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ABSTRACT 
Quorum sensing (QS) is a communication tool of bacteria that is involved in the 
regulation of bacterial virulence determinants, therefore making it an interesting target to 
attenuate pathogens. In this study, the anti-QS activities of four Malaysia‟s edible, local 
plants, namely, Melicopelunu-ankenda, Piper betle, Gnetumgnemon and Piper nigrum 
were explored by testing the hexane, chloroform and methanol extracts of the plants on 
Chromobacteriumviolaceum CV026, Escherichia coli [pSB401], E. coli 
[pSB1075],Pseudomonas aeruginosa PA01 and P. aeruginosaPA01lecA::lux. 
Qualitative studies of violacein inhibition of C. violaceum CV026 showed that most of 
the extracts except for the methanol extract of P. betle and chloroform and methanol 
extracts of G. gnemoninhibited the violacein productionin the presence of QS signals. 
On the other hand, quantitation assay on the violacein produced by C. violaceum CV026 
showed that M. lunu-ankenda chloroform and methanol extracts, all three extracts of P. 
betle and P. nigrum significantly inhibited the violacein synthesis. In the presence of QS 
signals, bioluminescence produced by E. coli [pSB401] was inhibited by all of the 
extracts while only P. betle hexane extract, G. gnemon chloroform and methanol extracts 
inhibited bioluminescence of E. coli [pSB1075]. All three extracts of M. lunu-ankenda 
and P. betle as well as chloroform extract of G. gnemon inhibited pyocyanin synthesis of 
P. aeruginosaPA01. lecA expression was significantly disrupted by the chloroform 
extracts of both G. gnemon and P. betle as well as the methanol extracts of P. betle. 
Swarming motility of P. aeruginosa PA01 was inhibited by the extracts of M. lunu-
ankenda (chloroform) and P. betle (methanol). Fractionation of chloroform extract of M. 
lunu-ankenda leads to a total of 14 fractions. These 14 fractions were then tested on E. 
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coli [pSB401], P. aeruginosaPA01lecA::lux and swarming motility of P. aeruginosa 
PA01. None of the fractions exhibited inhibition against lecAexpression. Fraction 4 and 
Fraction 11-14 showed inhibition against bioluminescence synthesis by E. coli [pSB401] 
while for swarming motility assay, only Fraction 5 and Fraction 11 showed observable 
inhibition. At this point of time, although the chemical nature of the anti-QS compounds 
from M. lunu-ankenda, P. betle,G. gnemon and P. nigrum are currently unknown, this 
study proves that local Malaysian plants could serve as leads in the search for anti-QS 
compounds. 
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ABSTRAK 
Pengesanan kuorum (QS) merupakan satu alat komunikasi bakteria yang terlibat 
dalam pengaturan penentu kebisaan bakteria, dengan itu menjadikan QS sebagai satus 
asaran yang menarik untuk melemahkan pathogen tersebut.Dalam kajian ini, aktiviti-
aktiviti anti-QS empat tumbuh-tumbuhan Malaysia yang boleh dimakan dan endemik, 
iaitu Melicopelunu-ankenda, Piper betle, Gnetumgnemon dan Piper nigrum telah 
diterokadengan menguji heksana, klorofom dan methanol ekstrak tumbuh-tumbuhan 
tersebut ke atas Chromobacteriumviolaceum CV026 , Escherichia coli [pSB401], E. coli 
[pSB1075], Pseudomonas aeruginosa PA01 danP. aeruginosaPA01lecA:: lux. Kajian 
kualitatif perencatan violacein C. violaceum CV026 menunjukkan bahawa kebanyakan 
ekstrak kecuali ekstrak methanol P. betle sertaekstrak kloroform dan methanol G. 
gnemon menghalang pengeluaran violacein itu.Selain itu, esei pengkuantitian violacein 
yang dihasilkan oleh C. violaceum CV026 menunjukkan bahawa ekstrak kloroform dan 
methanol M. lunu-ankenda, ketiga-tigaekstrak P. betle dan P. nigrum Berjaya 
menghalang pengeluaran violacein dengan ketara. Bioluminasi yang dihasilkan oleh E. 
coli [pSB401] telah dihalang pengeluarannya oleh semua ekstrak manakala hanya 
heksanaekstrak P. betle, ekstrak kloroform dan methanol G. 
gnemonberjayamenghalangpengeluaranbioluminasiolehE. coli [pSB1075]. Ketiga-
tigaekstrakM. lunu-ankendadanP. betle serta ekstrak kloroform G. 
gnemondapatmenghalangsintesispyocyaninP. aeruginosa PA01. Pengeluaran  leçA nyata 
diganggu oleh ekstrak kloroform kedua-duaG. gnemon dan P. betle serta ekstrak 
methanol P. betle. Motiliti berkerumun P. aeruginosa PA01 telah dihalang oleh 
ekstrakM. lunu-ankenda (klorofom) dan P. betle (methanol).Pemecahan  klorofom 
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ekstrak M. lunu-ankenda membawa kepada sejumlah 14 pecahan. Pecahan sebanyak 14 
ini kemudiannya diuji pada E. coli [pSB401], P. aeruginosa PA01lecA::lux dan motility 
berkerumun P. aeruginosa PA01.Tiada pecahan yang mempamerkan sebarang 
perencatan terhadap ungkapan lecA. Pecahan 4 dan Pecahan 11-14 menunjukkan 
perencatan terhadap sintesis bioluminasi oleh E.coli [pSB401] manakala bagi esei 
motility berkerumun, hanyaPecahan 5 danPecahan 11 menunjukkan perencatan yang 
ketara. Pada masa ini, walaupun sifat kimiasebatian anti-QS dari M. lunu-ankenda, P. 
betle, G. gnemon danP. nigrum kini tidak diketahui, kajian ini membuktikan bahawa 
tumbuh-tumbuhan tempatan Malaysia boleh dijadikan sebagai sumber pencarian untuk 
sebatian anti-QS.  
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CHAPTER 1 
INTRODUCTION 
 Quorum sensing (QS) is a system used by the bacteria to control the gene 
expression in response to cell density. QS is involved in many regulation of 
physiological functions such as bioluminescence, biofilm formation, sporulation, 
exchange of DNA and secretion of virulence factors, some may which contributes to 
bacterial pathogenesis (Henke & Bassler, 2004). Usage of antibiotics to counter bacterial 
infections has led to a rise in antibiotic-resistant pathogenic bacteria and this 
phenomenon pose as a global threat for public health management. As such, an 
alternative bacterial treatment that does not require inhibition or killing of bacterial 
growth is highly desirable as the evolutionary pressure to develop resistance towards 
these kinds of alternative treatment is much lower.  One of the available alternative 
treatments is by using anti-QS molecules, which can inhibit the virulence factors 
secreted by the infectious bacteria (Chong et al., 2011; Krishnanet al., 2012; Tanet al., 
2012).  
Malaysia has large flora diversity and four plants have been chosen to be tested 
for their anti-QS activities. Melicopelunu-ankenda (locally known as “tenggekburung”), 
Piper betle (locally known as “sireh”), Gnetumgnemon (locally known as “melinjau”) 
and Piper nigrum (locally known as “lada”) will be extracted with hexane, chloroform 
and methanol in order to obtain crude extracts with compounds of different polarity. 
These crude extracts will be tested on anti-QS assays involving bioluminescence, 
violacein, pyocyanin, swarming and lecA expression. Fractionation of the active crude 
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extract will be carried out using Agilent Technologies 1260 Infinity Series HPLC system 
(Agilent Technologies, Germany). Then, fractions shall be tested on some anti-QS 
bioassays to determine which fraction contains the active compounds that have anti-QS 
abilities. The anti-QS compounds from these four Malaysia local plants may be a new 
class of non-bacterial origin antagonist and more of the local plants should be screened 
for anti-QS activities.  
The objectives of this study are as follows:  
1. To screen and identify plant samples that show anti-QS activities. 
2. To attenuate QS-mediated virulence of P. aeruginosa PA01. 
3. To fractionate the plant extract that gives significant anti-QS results and identify 
which fraction that has the active compounds. 
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CHAPTER 2 
LITERATURE REVIEW 
2.1 Quorum Sensing 
Bacteria are constantly exposed to multiple environmental challenges such as 
fluctuation in nutrient availability, temperature, pH, osmolarity and other forms of 
stimuli. Eventually, bacteria develop complex systems that enable them to achieve 
homeostasis in these harsh environments. QSis a cell-to-cell communication tool used 
by the bacteria to produce extracellular signaling molecules which enables it to monitor 
its population density. As the population density increases, the amount of extracellular 
signaling molecules in the environment increases as well. When the concentration of 
these signaling molecules reaches a certain threshold level, the bacteria specific target 
gene will be activated (Henke & Bassler, 2004; Miller & Bassler, 2001; Waters & 
Bassler, 2005).     
The genes that are activated as a result of QS leads to the expression of 
physiological processes such as bioluminescence, swarming, swimming, twitching, 
biofilm formation, production of antibiotics, plasmid conjugal transfer, pyocyanin and 
elastase production (Whiteheadet al., 2001; Danielset al., 2004; Parsek & Greenberg, 
2005; Antuneset al., 2010). QS was first discovered from Vibrio fischeri, a 
bioluminescent marine bacteria. V. fischeri colonizes the light organ of Euprymna 
scolopes and when the density of the bacteria is high, QS induces genes expression 
required for luminescence.Gram-negative and gram-positive bacteria use different kind 
signaling molecules where the former utilizes N-acyl-homoserine lactones (AHLs) 
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which are from a group of fatty acid derivatives while the latter uses post-translationally 
processed peptides for QS (Figure 2.1). In Gram-negative bacteria, the AHLs in the 
environment will diffuse freely into the cell and then binds to specific receptor which 
acts as a transcriptional activator. The binding will then cause an allosteric regulation of 
proteins to happen, that will lead to activation of genes including those responsible for 
AHLs synthesis. As for the post-translationally processed peptides used by the Gram-
positive bacteria, these peptides do not diffuse into the cell, but they will bind to the 
specific receptors that can be found on the membrane. This will then cause a cascade 
activation of signal transduction pathway that leads to change in genes regulations. The 
agr gene of the staphylococcal bacteria is an example QS system which exists in Gram-
positive bacteria (Novick & Geisinger, 2008; Waters & Bassler, 2005). 
 
 
Figure 2.1: The general QS system in (a) Gram-negative bacteria and (b) Gram-
positive bacteria (Bassler, 1999). 
 
 
 
(a) (b) 
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2.2 AHL Biosensors 
 AHL biosensors such as C. violaceum CV026,Escherichia coli [pSB401] and E. 
coli[pSB1075] relies on exogenous AHLs for QS to occur as these bacteria lack of the 
synthase gene requires for AHLs synthesis. C. violaceum CV026 is a gram negative 
bacterium that produces violacein, a purple pigmented compound in the presence of 
short chain AHLs ranging from N-butanoyl homoserine lactone (C4-HSL) to N-octanoyl 
homoserine lactone (C8-HSL) with different level of sensitivity. It was found that C. 
violaceum CV026 responds best to N-hexanoyl homoserine lactone (C6-HSL) (McClean 
et al., 1997). E. coli [pSB401] and E. coli [pSB1075] produces luminescence in the 
presence of N-3-oxohexanoyl-L-homoserine lactone (3-OC6-HSL)and N-3-
oxododecanoyl-L-homoserine lactone (3-OC12-HSL) respectively(Winson et al., 1998).  
These biosensors are used to determine whether the plant extracts or compounds 
possess anti-QS properties. In the study conducted by Zhu and Sun, violacein formation 
by C. violaceum CV026 was quantified after incubation with Tremella fuciformis extract 
and it was found that the violacein formed was significantly reduced. Thus, it was 
concluded in this study that compounds extracted from T. fuciformis could inhibit a QS-
regulated behavior in C. violaceumCV026(Zhu & Sun, 2008).  
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2.3 Anti- Quorum Sensing 
 In an environment where resources are limited and bacteria have to compete for 
these resources, the bacteria which have the capability to disrupt QS may have higher 
chances for survival over other species that relies on QS (Waters & Bassler, 2005). 
Disruption of QS or anti-QS can be achieved via a few ways. Firstly, competitive 
inhibition between signaling molecules for the receptor as well as degradation of 
signaling molecules by enzymes can cause anti-QS to happen. For example, enzymes 
involved in AHLs degradation include AHLs lactonase and acylase (Kaliaet al., 2011). 
Besides that, by targeting the enzymes responsible for the production of these signaling 
molecules, bacterial QS can be inhibited. This involves inhibition of the enzymes 
responsible for the production of acyl chain, S-adenosylmethionine synthase and LuxI 
homolog proteins. AHLs are derivatives of S-adenosylmethionine. LuxI-based enzymes 
bind the acyl group from a specific acylated acyl carrier protein to the methionine on S-
adenosylmethionine. Lactonization of the intermediate results in the synthesis of AHLs 
(Honget al., 2012; Parveen & Cornell, 2011; Bassler, 2002). Besides that, blocking 
AHLs from forming AHL-receptor complex can also prevent QS from happening (Koch 
et al., 2005).  
 Since interference with QS showed much potential in controlling undesirable 
microbial activity and many opportunistic pathogenic bacteria rely on QS to regulate 
their virulence expression, various works has been carried out to identify compounds 
that have anti-QS activity. Compounds which can inhibit QS are known as QS 
inhibitors. QS inhibitors do no kill or inhibit bacterial growth and thus reduced the 
evolutionary pressure of the bacteria to develop resistance (Issac et al., 2011).  
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The first QS inhibitor compound, halogenated furanones (Figure 2.2 (a))was 
isolated from Delisea pulchra, a marine red alga which can be found in Australia. These 
furanones have structures which are similar to AHLs and has been shown to be able to 
inhibit QS expression through the displacement of AHLs from the receptor (Manefield 
et al., 1999). By displacing the AHLs from its receptor competitively, D. pulchra is able 
to promote the rate of proteolytic degradation without inhibiting the bacterial 
growth(Manefield et al., 2002). Isolated furanones interferes with Serratia liquefaciens 
swarming activity while synthetic derivatives of the halogenated furanones has been 
shown to interfere with biofilm production in P. aeruginosa(Hentzer et al., 2002; 
Rasmussen et al., 2000).Plants derived extracts and compounds have been extensively 
tested for anti-QS due to their traditional pharmacological values. Besides, active 
compounds with anti-QS activities derived from plants are deem safe as these plants are 
normally eaten by humans. Malabaricone C (Figure 2.2 (b)) is a pure compound isolated 
from the bark of nutmeg tree, Myristica cinnamonea that has anti-QS activity. 
Malabaricone C inhibited the production of the purple pigment, violacein by 
Chromobacterium violaceum CV026 in the presence of QS signal, pyocyanin and 
biofilm synthesis in P. aeruginosa PA01 (Chong et al., 2011) 
 
Figure 2.2: Structure of (a) halogenated furanones with structural variations and 
(b) malabaricone C (Adapted from Manefield et al., 1999; Chong et al., 2011). 
 
(a) (b) 
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2.4 Pseudomonas aeruginosa 
P. aeruginosa is the most common Gram-negative bacterium that has been 
linked to cause nosocomial infections, particularly in immunocompromised patients. P. 
aeruginosahas been reported to be responsible for nosocomial pneumonia 
cases,hospital-acquired urinary tract infections, surgical wound infections and 
bloodstream infections (Micek et al., 2005; Mikuniya et al., 2007; Sadikot et al., 2005). 
 Neutropenic cancer and bone marrow transplant patients are more vulnerable to 
be exposed to P. aeruginosa infections. At the same time, P. aeruginosais also one of 
the most typical and lethal pathogens responsible for ventilator-associated pneumonia 
intubated patients, with direct attributed death rates reaching 38% (Dunn & Wunderink, 
1995; Hauser et al., 2002; Parkinset al., 2010; Paterson, 2006). The ability of P. 
aeruginosa to express these diverse and severe infections is due to a wide range of 
virulence factors. Collectively, these virulence factors are causing extended tissue 
damages in not only humans, but also other mammals (Van Delden & Iglewski, 1998). 
 P. aeruginosa cell surface virulence factors such as flagella, pili, 
lipopolysaccharide and alginate are responsible for movement, progression, adhesion 
and colonization towards surface contact with other bacteria (Kipniset al., 2006). Found 
on the cell surface of P. aeruginosa, the flagella are made of protein complex body 
which forms a filamentous polar appendage. These filamentous polar appendages assist 
P. aeruginosa motility through a propeller or screw-like motion while swimming 
(Feldman et al., 1998; Toutainet al., 2007). The flagella not only function in locomotion 
of P. aeruginosa as they also participate in pathogenesis and cause inflammation which 
leads to interleukin-8 production (Adamoet al., 2004; DiMangoet al., 1995).  
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 Twitching motility of P. aeruginosa is due to the retractile properties of pili or 
frimbriae. Airways can be colonized quickly through this characteristic and asialoGM1 
plays an important role in pili during adhesion phase (Burrows, 2012; Guptaet al., 1994). 
Therapeutic drugs have been targeting flagella and pili of P. aeruginosa as these 
characteristics seem to be playing a crucial role in the bacterial virulence (Döring & 
Pier, 2008). One of the components in lipopolysaccharide is known as Lipid A, whereby 
Lipid A can cause activation of many pro-inflammatory systems (Kipnis et al., 2006).   
In the year 2000, the completion of the P. aeruginosaPA01 genome sequence 
gave a global view into the basis for its flexibility and resilience towards antibiotics 
resistance. The large genome of P. aeruginosaPA01 contains a comparatively large 
number of genes that are thought to encode regulators of gene expression(Stover et al., 
2000). Regulation of the genes that are encoding the virulent factors is heavily 
dependent on the signaling system that consists of at least two categories of LuxR-LuxI 
homologues.  
P. aeruginosa consists of las(LasI and LasR) and rhl (RhlI and RhlR) QS 
system. The cell-to-cell signaling system described in P. aeruginosa was firstly shown 
in regulation of LasB elastase and thus, named the las system (Passadoret al., 1993). 
LasI (signal synthase) of P. aeruginosais responsible for the synthesis of 3-OC12-HSL 
and LasR is the corresponding transcriptional activator (Schuster &Greenberg, 2006). 
When 3-OC12-HSL binds to the signal receptor, LasR, transcription of certain specific 
genes is activated. This activation has been shown to require 3-OC12-HSL-dependent 
multimerization of LasR (Kiratisinet al., 2002). 
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The lassystem coordinates the virulence expression of LasA elastase, LasB 
elastase, endotoxin A and alkaline protease in P. aeruginosa(Williams & Cámara, 
2009).The expression of LasI is very sensitive to concentration of LasR-3-OC12-HSL 
complex. An increment in LasI synthesis will eventually lead to a rapid increase in 3-
OC12-HSL expression and subsequently, increase the formation of LasR-3-OC12-HSL 
activator complex. This autoregulatory loop showed that the activation of las-dependent 
virulence factor expression is correlated closely with 3-OC12-HSL availability in the 
surrounding environment (Pesciet al., 1997; Seedet al., 1995; Venturi, 2005).This 
autoinduction hierarchy of las system has been shown to activate the xcpP and xcpR 
genes that encode proteins of the P. aeruginosa secretory pathway. These genes are 
involved in the Type II secretion system to discharge extracellular proteins in P. 
aeruginosa surrounding environment. There are six types of secretion systems that have 
been described in Gram-negative bacteria and of the six secretion systemP. aeruginosa 
displays five of those systems (Bleves et al., 2010; Chapon‐Hervé et al., 1997). 
Another signaling system in P. aeruginosa is known as the rhl system due to its 
ability to control the production of rhamnolipid. The rhl system consists of the signal 
synthase RhlI and the signal receptor RhlR. RhlI produces C4-HSL, which will bind to 
RhlR, causing the activation of certain gene expression (Kievitet al., 2006; Pesci et al., 
1997).It was found that RhlR requires C4-HSL for transcriptional activation but not 
necessary for dimerization(Ventre et al., 2003). C4-HSL interacts with RhlR in order to 
activate the expression of rhlAB, which is the operon encoding a rhamnosyltransferase 
required for the production of rhamnolipid biosurfactant. When the rhamnolipid 
biosurfactant is present, it enables P. aeruginosa cells to swarm across semi-solid 
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surfaces (Dézielet al., 2003; Ochsner & Reiser, 1995; Soberon-Chavezet al., 2005). 
Functions controlled by rhl QS systems include expression of alkaline protease, 
pyocyanin, hydrogen cyanide, lectins and elastase (Juhaset al., 2005).  
The las and rhl systems had been shown to be involved in the expression of 
alkaline protease and elastase and subsequent studies were conducted to define the 
relationship between the two systems. The two QS systems has been shown to be 
coordinating each other in a hierarchical way whereby the LasI-LasR system positively 
controlling the activity of RhlI-RhlR system (Rasmussen & Givskov, 2006). 
In 1999, Pesci and his collegues found another type of P. aeruginosa signaling 
molecules known as 2-heptyl-3-hydroxy-4-quinolone or Pseudomonas quinolone signal 
(PQS). This molecule was found to be involved in the gene expression of lasB which 
encodes for LasB elastase (Pesci et al., 1999).PQS has a high affinity for lipid-rich 
membranes of bacterial cells as it is a hydrophobic molecule with low solubility in 
water(Lépineet al., 2003). As PQS synthesis and expression is mediated by las and rhl 
systems respectively, these three systems should be inter-related to one another. 
Expression of lasB was further amplified by the combined effect of C4-HSL and PQS as 
compared to with either C4-HSL or PQS alone (Diggleet al., 2006).  
Pyocyanin is a QS-regulated trait and it is a blue redox-active secondary 
metabolite produced by P. aeruginosa. It can be found in large quantities in the sputum 
of cystic fibrosis patients that had been infected by P. aeruginosa. Pyocyanin not only 
affects regulation of ion transport, frequency of ciliary beats and secretion of mucus in 
airway epithelial cells by altering the cytosolic concentration of calcium but also 
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interferes with gene expression and innate immune mechanism (Rada & Leto, 2013). 
Pyocyanin production involves a series of complicated steps which are assisted by the 
gene products encoded by twophzABCDEFG operons and by the phzH(encodes putative 
phenazine-specific methytransferase),phzM(encodes flavin-containing monooxygenase) 
and phzS genes, which modifies the precursors into tricyclic compounds (Mavrodi et al., 
2001). 
The final steps in pyocyanin synthesis are catalyzed by phzM and phzS operons. 
Pyocyanin production is positively regulated by the LysR-like transcriptional activator 
MvfR (PqsR) through the synthesis of PQS molecules, with additional regulatory signals 
from the LasR-LasI, RhlR-RhlR, GacA-GacS and Vfr regulatory system. The LysR 
transcription factor, MvfR regulates the production of quinolones and in return, the PQS 
positively regulates the expression of rhlsystem(Cao et al., 2001; Gallagheret al., 2002; 
McKnightet al., 2000). 
It has been a difficult to discern the role of pyocyanin during lung infection as P. 
aeruginosa infection is multifactorial and genes involved have pleiotropic 
characteristics. To overcome this problem, many studies used in vitro cell culture 
systems with purified pyocyanin to determine the toxicity level of pyocyanin. Through 
these studies, it was shown that an extensive range of cellular damage was caused by 
pyocyanin and this maybe the causal factor that contributes to the persistency of P. 
aeruginosa in the lungs of cyctic fibrosis patients. Purified pyocyanin can be obtained 
through repeated chloroform-distilled water extraction cycles from the stationary phase 
of P. aeruginosa cultures.Absorption spectrum of pyocyanin is pH-dependent and at low 
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pH values, extracted pyocyanin is red while in high pH values, they are blue (Lau et al., 
2004; Rada & Leto, 2013). 
In A549 human alveolar epithelial cell line and human bronchial epithelial cells, 
it was shown that pyocyanin inactivates the activity of catalase but have no effect 
against manganese superoxide dismutase or copper-zinc superoxide dismutase. 
Pyocyanin not only inhibits catalase functions in cell-free system, but it also lowers the 
transcription of the genes encoding catalase (O'Malley et al., 2003).A certain 
concentration of pyocyanin recovered from the sputum of cystic fibrosis patients has 
been shown to induce apoptosis of neutrophils. Results showed that the rate of apoptosis 
activation is concentration and time dependent whereby within five hours of exposure to 
50 µM of pyocyanin, the apoptosis induction increased 10 fold. Since the apoptosis 
caused by similar concentration of pyocyanin only affects neutrophils and not monocyte-
derived macrophage or airway epithelial cells, it was concluded that these form of 
apoptosis induction are cell-type dependent and this discovery was found to be 
interesting(Usher et al., 2002). On top of that, an in vivo study which compares the 
neutrophils clearance in mice affected with wild-type and pyocyanin-deficient strains of 
P. aeruginosa showed that mice affected with wild-type strains has a much higher 
percentage of neutrophils apoptosis. P. aeruginosa, through pyocyanin production, 
significantly reduced the acute inflammatory response by accelerating apoptosis of 
neutrophils. By doing so, P. aeruginosa has a higher chance of survival (Allen et al., 
2005). 
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 Swarming is a one of the possible QS-regulated phenotypes in P. aeruginosa.  
Swarming consists of a flagella-driven movement of differentiated swarmer cells 
(hyperflagellated, elongated, multinucleated) which enables bacteria to span over a 
semisolid surface as biofilms (Daniels et al., 2004). QS regulation of swarming motility 
allows the optimal dissemination of bacterial cells when a population is getting too large 
to inhabit a single niche or when the nutrients in the environment no longer suits their 
needs (Daniels et al., 2004; Déziel et al., 2003). 
Swarming of P. aeruginosa is induced over a semisolid surface (0.5-0.7% agar). 
It was found that cells that are isolated from the swarm edge and the center possess two 
polar flagella (Kohleret al., 2000). Swarming is dependent on flagella and type IV pili 
whereby these two components facilitate the swarming motion (Overhageet al., 2008). 
In swarming motility of P. aeruginosa, rhamnolipid function as wetting agents by 
reducing the surface tension.Rhamnolipid is rhamnose-containing glycolipid 
biosurfactant and it has a detergent-like structure (Soberon-Chavez et al., 2005).The loss 
of lung biosurfactant may be the cause of atelectasis that has been associated with 
chronic and acute P. aeruginosa infection. In addition, rhamnolipid was also found to be 
inhibiting the mucociliary transport as well as the ciliary function of human respiratory 
epithelium (Abdel-Mawgoudet al., 2010; Read et al., 1992). 
In general, the two more abundant rhamnolipids are rhamnosyl-beta-hydoxy-
decanoyl-beta-hyroxydecanoate (a mono-rhamnolipid) and rhamnosyl-rhamnosyl-beta-
hydroxydecanoyl-beta-hydroxydecanoate as revealed by mass spectrometry (Soberon-
Chavez et al., 2005). The rhlAB operon, an rhlIR-mediated target gene, catalyzes the 
synthesis of mono-rhamnolipid (L-rhamnosyl-beta-hydoxydecanoyl-beta-
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hyroxydecanoate) from dTDP-L-rhamnose and 3-(3-hydroxyalkanoyloxy)alkanoic acid 
(HAA) moieties from various lengths (Ochsner & Reiser, 1995). HAAs are the 
rhamnolipid anabolic precursor in rhamnolipid biosynthesis and they display evident 
surface-active characteristics. It was found that rhlA is required for the production of 
HAA. The same study also observed that swarming requires the expression of rhlA but 
does not necessitate rhamnolipid production because HAA alone can act as 
surfactants(Déziel et al., 2003).  
Besides needing rhamnolipid biosurfactant for swaming motility, P. aeruginosa 
also need FlhF, a signal recognition particle-like protein. FlhF is required for the 
transcription of certain class of genes in flagella and thus absence of FlhF will cause 
disruption in the movement (Murray & Kazmierczak, 2006). To add on, type IV pili 
assists the flagella in surface propagation and it could be involved in the sensing of 
viscosity of the surface and sensing a signal for initiation of swarming. In the absence of 
flagella and type IV pili, P. aeruginosa moves in sliding motion instead of swarming 
motility (Köhleret al., 2000; Murray & Kazmierczak, 2008). 
 Biofilms are made of colonies of microorganisms embedded in a matrix of 
extracellular polymeric substances, in which they accumulate rapidly in watery 
favorable physiological conditions surfaces (Kuehn et al., 1998).P. aeruginosaforms 
biofilm for defense purposes (protect itself from hostile environment in the host), 
colonization (isolation to a nutrient-rich area) and utilization of cooperative advantages 
through the community of bacteria. Biofilms are able to resist the shear forces produced 
by blood flow and the washing action of saliva. On the other hand, the bacteria kept 
within the biofilms can withstand deprivation of nutrients, changes of pH, oxygen 
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radicals, disinfectants and antibiotics better than planktonic organisms. The important 
trait that further strengthens biofilm resistance is the sticky matrix which may contain 
DNA and other polymers, but in general, it is predominantly composed of 
exopolysaccharides (Jefferson, 2004). The development of adhesins and motility factors 
are suppressed once biofilms formation has been established. This suggests that the 
prominent role of adhesins, pili and flagella is for initial attachment, but once the 
development of the biofilm has surpass this stage, the proteins are no longer needed and 
their expressions are inhibited (Lejeune, 2003).  
Exotoxin A, which is produced by most P. aeruginosastrains can cause clinical 
infections. The exotoxin A catalyzes adenosine diphosphate-ribosylation and 
inactivation of elongation factor 2, which could lead to inhibition of protein biosynthesis 
and cell death. Exotoxin A that has been purified was found to be highly lethal for mice 
and this supports the major role of exotoxin A as the systemic virulence factor of P. 
aeruginosa(Van Delden & Iglewski, 1998).  
During P. aeruginosa infection, proteases play a major role and the type of 
proteases that are produced by P. aeruginosa includes LasB elastase, LasA elastase and 
alkaline protease(Van Delden & Iglewski, 1998). P. aeruginosa ability to destroy 
protein elastin during acute infection is a major virulence determinant. Elastin makes up 
a major part of human lung tissue and it is responsible for lung expansion and 
contraction. Consequently, the blood vessel relies on elastin due to its resilience, thus 
making elastin an important component in blood vessels. LasB elastase and LasA 
elastase synergistically causes elastolytic activity (Galloway, 2006). 
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 LasB elastase is a zinc metalloprotease that acts on a number of proteins 
including elastin and it is highly efficient. LasB has a proteolytic activity of 
approximately 10 times that of P. aeruginosa alkaline protease and an activity toward 
casein of approximately four times that of trypsin (Galloway, 2006). On the other hand, 
LasA elastase is a serine protease that acts in a concerted action with LasB elastase to 
degrade elastin. LasA elastase nicks elastin and caused elastin to be sensitive to 
degradation by other proteases such as LasB elastase, alkaline proteases and neutrophil 
elastase (Van Delden & Iglewski, 1998). 
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2.5 Melicope lunu-ankenda 
 
Figure 2.3: M. lunu-ankenda (Gaertn.) T. G. Haertly plant voucher that has been 
deposited into Herbarium of University Malaya. 
 
M. lunu-ankenda (Gaertn.) T. G. Haertly (Figure 2.3) is locally known as 
„tenggek burung‟. It is a medium-sized tree, with trifoliate leaves and small, greenish 
white flowers. The roots, roots bark, stem wood, leaves and flowers are used in Indian 
traditional medicine for fever, as tonic and for improving complexion (Johnson et al., 
2010). 
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 The young leaves of M. lunu-ankendaare usually eaten raw as „ulam‟ by some 
local Malaysians and it was said to be able to reduce hypertension and revitalize the 
body. The leaves extract of M. lunu-ankenda were found to contain different mixtures of 
hydrocarbons and squalenes, fatty acids and esters. The major compound that was 
isolated was a geranylated coumaric acid (Ramliet al., 2004). Previous study had 
isolated three phenylethanones, five furoquinoline alkaloids, bergapten and lupeol from 
the root bark of M. lunu-ankenda. Some of the phenylethanones isolated showed 
fungicidal activity (Kumaret al., 1990). Past studies has shown that the extract of M. 
lunu-ankendaexhibits antioxidant, antipyretic, analgesic and anti-inflammatory 
properties (Johnson et al., 2010).  
 
 
 
 
 
 
 
 
 
 
42 
 
2.6 Piper nigrum 
 
Figure 2.4: P. nigrum L. plant voucher that has been deposited into Herbarium of 
University Malaya.  
 P. nigrum is in the family of Piperaceae and it is a flowering vine. It is usually 
cultivated for the fruits (peppercorn) and when the peppercorns fully mature, they are 
dark red in color. Piper species are widely distributed in the tropical and subtropical 
regions of the world and have multiple applications in different folk medicines. In 
traditional Chinese medicine, many species are used to treat inflammatory diseases 
(Stöhret al., 2001).P. nigrumis a natural spice widely used in the Ayurvedic medicine. It 
is used in treatment for asthma, cough, diabetes and heart problem(Chatterjee et al., 
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2007). Due to the medicinal benefits of P. nigrum compounds, dozens of studies has 
been performed to identify the compounds available in P. nigrum. The types of 
compounds that can be found in P. nigrum include piperidine and pyrrolidine alkamides. 
Piperine which exists in P. nigrum is able to act as an analgesic, antipyretic and 
actifeedant (Parmar et al., 1997). Research also showed that piperine can act as a 
suitable template for the development of therapeutics drugs for trypanocidal infection 
treatment (Ribeiro et al., 2004). Eugenol, myristicin, safrole, monoterpenes, oxygenated 
sesquiterpenes and β-caryophyllene to name a few, are among the many compounds of 
P. nigrum that has been identified over the years (Jirovetz et al., 2002) 
 
 
 
 
PP 
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2.7 Piper betle 
 
Figure 2.5:P. betle L. plant voucher that has been deposited into Herbarium of 
University Malaya.  
 P. betle belongs to the family of Piperaceae (same as P. nigrum) and it is a 
perennial dioecious, semi woody climber. The stems of P. betle are swollen at the nodes 
and papillose when young. The stems will then grow to form a glabrous morphology. 
The leaves (heart-shaped) of P. betle have a petiole of approximately 1-2 cm long and 
1.2-1.8 mm thickness when dry and glabrous at maturity. Cultivation of P. betle 
predominantly takes place in Sri Lanka, India, Malay Peninsula, Philippine and East 
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Africa. The fundamental part of the leaves of P. betle is the betel oil. Betel oil has a 
clove like flavor and comprise of terpenes and phenols. Betel leaves are consumed 
among the Southeast Asians population and it is usually taken with areca nut, slaked 
lime or tobacco (Arambewela et al., 2005).  
 Betel oil is a volatile oil and it has high safrol content. Besides that, eugenol, 
allyl diacetoxy benzene and chavibitol acetate were also found in betel oil. Studies have 
shown that the extract of P. betle leaves possess antidiabetic, gastroprotective, wound 
healing, hepatoprotective, antiallergic and antioxidant charateristics (Arambewela et al., 
2005; Dasgupta & De, 2004; Milton et al., 2012; Wirotesangthonget al., 2008). Betel 
juice can also be given to children as a treatment for cough and admistered on to the eye 
for treating night blindness in adults. On top of that, betel juice is also used to treat 
inflammation of the mucus membrane in the airways or the body cavities (Arambewela 
et al., 2005; Jayaweera, 1982). 
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2.8 Gnetum gnemon 
 
Figure 2.6: G. gnemon L. plant voucher that has been deposited into Herbarium 
of University Malaya.  
 G. gnemon(family of Gnetaceae) is commonly found in Southeast Asia and is 
used as food in Indonesia. It is a medium-size tree and can grow up to 15-20 m tall. G. 
gnemon is an aboreal dioecious plant.  The leaves are evergreen and when mature, it 
forms a glossy dark green color. The strobilus has a large seed and this seed can be 
eaten.G. gnemon is a very popular food in Indonesia and the seeds are ground into flour 
47 
 
and deep-fried as crackers while the leaves are used for vegetable dishes (Iliya et al., 
2003; Katoet al., 2009). The acetone and methanol extracts of G. gnemon roots yield 
four stilbene derivatives, namely gnemonols K and L (resveratrol trimers), M 
(isorhapontigenin dimer) and gnemonoside K (glucoside of resveratrol trimer); 11 
known stilbenoids; a lignan. Some of these compounds have antioxidant properties (Iliya 
et al., 2003). 
 On the other hand, isolation of C-glycosylflavones was first reported from the 
leaves of G. gnemon in 1978(Wallace & Morris, 1978). Besides being traditionally used 
in the treatment of arthritis, bronchitis and asthma, G. gnemon compounds were shown 
to be able to lower the blood sugar level, cause apoptosis of colon cancer cells and have 
anti-inflammatory activity (Kato et al., 2009) 
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2.9 High Performance Liquid Chromatography (HPLC) 
 Chromatography refers to the separation of the elements of a sample partition 
between two phases, namely the stationary phase and the mobile phase (gas, liquid or 
supercritical fluid). Chromatography can be divided into difference categories such as 
adsorption, partition and ion-exchange chromatography. Liquid chromatography (LC) is 
a technique in adsorption chromatography in which the mobile phase is in liquid form 
and it can divided further into normal phase LC and reverse phase LC based on the 
polarity of the mobile phase. Traditional LC consists of a glass column that has been 
filled with slurry of porous solid material. Samples to be separated are firstly dissolved 
in appropriate solvents and applied directly to the top of the column(Chromatography, 
2013; McMaster, 2007). 
 The adsorbent (stationary phase) is usually made of aluminium oxide or silica 
gel. Slurry of the adsorbent that has been mixed with the mobile phase is poured into the 
column and a layer of sand is placed at the top of the column. Samples (dissolved in 
solvents) to be separated is distributed evenly at the top of the column and as the mobile 
phase passes through the column,  compounds with weaker adsorption will move at a 
faster rate as compared to the compounds with stronger adsorption. By changing the 
polarity of the mobile phases, separation of complex mixtures can be done. The type of 
mobile phases to be used is dependent on the compounds in the samples to be separated. 
Polarity of solvents normally used in LC in increasing order is as follows:  petroleum 
ether > carbon tetrachloride > hexane > carbon disulfide > benzene > toluene > 
methylene chloride > chloroform > diethyl ether > ethyl acetate > acetone > ethanol > 
methanol > water (General principles of chromatography, 1997; McMaster, 2007).  
49 
 
HPLC instrument was first constructed by Csaba Horvath in 1964 and current 
improved HPLC has higher resolving power, faster separation, able to perform efficient 
qualitative and quantitative measurements and isolation and automation of methods and 
data analysis as compared to traditional LC. Analytical HPLC typically uses column of 
smaller size, lower flow rate, lower injection sample volume and concentration but 
better resolution as compared to preparative HPLC. Scale-up from analytical to 
preparative HPLC enable us to quantitate the desired separated compounds. Main 
components of HPLC are reservoir, degasser, pumps, autosampler/manual injector, 
column, guard column, detector and fraction collector. Mobile phases is placed in the 
reservoir and for analytical analysis, acids are added into the mobile phase to produce 
better chromatographic results (Gupta & Shanker, 2008). 
 HPLC pumps ensure consistent delivery and flow rate of the mobile phases 
throughout the whole separation process. An autosampler is able to work without 
operator attendance once the settings has been made and sample will be injected into the 
system and continuously separated without hassle. Generally, HPLC columns consist of 
silica bonded-phase columns. Carbon-18 (C-18) column are made of silica packing that 
has been attached to octyldecyl carbon units, making it to have high affinity to nonpolar 
compounds(Comparison guide to C18 reversed phase HPLC columns, 2008; McMaster, 
2007).  
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Detectors of HPLC should not react with the mobile phases (no peak should be 
detected) and should be able to detect a wide range of compounds. Among the type of 
detectors available for HPLC systems include ultraviolet/visible light spectroscopy; 
refractive index; flurorescence; electrochemical; evaporative light scattering; 
conductivity; mass; infrared detectors (Various detectors used in the high performance 
liquid chromatography with comparison to their sensitivity, 2013).  
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CHAPTER 3 
MATERIALS AND METHODS 
3.1 Chemical Reagents 
 Chemical reagents used in this study were purchased from Merck, Germany; 
Sigma Chemical Corp., USA; BDH Laboratory Supplies, England; and Ajax Pacific 
Specialty Chemicals Limited ABN., Australia. 
3.2 Growth Media and Agar 
Preparation of the growth media and solutions stated in this study required 
sterilization by autoclaving at 121 
˚
C, 15 psi for 20 min. Sterilization of heat sensitive 
solutions was done via filter sterilization with syringe filter at pore size of 0.22 µm. 
3.2.1 Luria-Bertani (LB) Medium 
Luria-Bertani broth (LBB) was prepared by adding  1.0 % w/v trytone, 1.0 % 
w/v NaCl and 0.5 % w/v yeast extract into 1 litre of distilled water. On the other hand, 
LB agar was prepared by adding Bacto agar to a final concentration of 1.5 % w/v into 
the LBB. Supplementation of antibiotics was done after autoclave sterilization of the 
medium. 
3.2.2 Swarming Agar 
 Swarming agar was prepared by adding glucose (1% w/v), Bacto agar  
(0.5% w/v), Bacto peptone (0.5% w/v) and yeast extract (0.2% w/v) into 1 litre of 
distilled water and autoclaved.  
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3.3 Stock Solutions 
3.3.1 Synthetic N-acyl-homoserine Lactones 
Synthetic AHL molecules were obtained from Sigma-Aldrich
©
 and Cayman 
Chemicals. Resuspension of the powder was performed using acetonitrile (ACN) to the 
desired concentration. 
3.3.2 Kanamycin and Chloramphenicol Stock Solution 
Kanamycin and chloramphenicol stock solution was prepared by dissolving in 
sterile distilled water and ethanol respectively resulting in the final concentration of 100 
mg/ml. The antibiotic stock was filter sterilized into new sterile microcentrifuge tubes 
followed by storage of the aliquots at -20 ˚C until further usage. 
3.3.3 Preparation and Dilution of Plants Stock Solution 
The dried crude extract was weight 10 mg and dissolved in 1 ml of absolute 
dimethyl sulfoxide (DMSO) to prepare a 10 mg/ml sample stock solution which was 
then kept in a 1.5 ml microcentrifudge tube. The tube which contained the stock solution 
was mixed well by vortex machine. Once labeled, the sample tube was stored at -20˚C 
freezer. Prior to be used, the plants extract was diluted with sterile distilled water to 
desired concentration.  
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3.4 Bacterial Strains 
   Table 3.1: Bacterial strains used in this study. 
Strain Description 
Source/Referen
ce 
C. violaceum 
CV026 
Double mini-Tn5 mutant derived from ATCC 31532, 
Kan
R
, Hg
R
, cvil::Tn5xylE, plus spontaneous Str
R
 AHL 
biosensor, produces violacein pigment only in the 
presence of exogenous AHL 
(McClean et al., 
1997) 
P. aeruginosa 
PA01 
lecA::lux 
 
Prototroph 
lecA::luxCDABEgenomic reporter fusion in PA01 
 
 
(Winzer et al., 
2000) 
E. coli 
 
[pSB401] 
 
 
[pSB1075] 
 
luxRluxl‟(Photobacterium 
fischeri[ATCC7744])::luxCDABE (Photorhabduslumi
nescens [ATCC 29999]) fusion; pACYC184-derived, 
Tet
R
, AHL biosensor producing bioluminescence 
lasRlasl‟ 
(P. aeruginosa PAO1)::luxCDABE(P.luminescens [A
TCC 29999]) fusion in pUC18 Amp
R
, AHL biosensor 
 
(Winson et al., 
1998) 
 
 
(Winson et al., 
1998) 
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producing bioluminescence 
 
 Bacteria were grown in LBBin shaking (220 rpm) incubator. C. 
violaceumCV026 was cultured in 28 ˚C, while P. aeruginosastrains at 37 ˚C. C. 
violaceumCV026growth medium was supplemented with kanamycin (30 µg/ml) and 
chloramphenicol (30 µg/ml). 
3.5 Identification and Processing of Plant Samples 
Plant samples used in this study were purchased from the farmer‟s market in 
Petaling Jaya, Selangor.Voucher specimen of each plant samples was deposited in the 
Herbarium of University of Malaya for proper identification.  Fresh plant samples were 
washed, cut into small pieces and dried in hot air oven (45 ˚C) for 3 days. 
3.6 Extraction of Dried Samples by Infusion 
Dried samples(Leaves of M. lunu-ankenda, P. betle and G. gnemon; Seeds for P. 
nigrum) were blended to fine powder and submerged sequentially in solvent (ratio 1:10 
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w/v), namely, hexane, chloroform and methanol. Infusions were filtered using Whatman 
No. 1 filter paper to obtain filtrate which contained solvent and secondary metabolites 
extracted from the dried samples. Filtrates were concentrated in vacuum using a rotary 
evaporator to yield crude extract with traces of solvent. First, a little extraction was 
transferred into a round bottom flask and the mouth of the round bottom flask was 
locked to the condenser part of the rotary evaporator. The extraction was heated in 45-50 
˚C water bath in the electric heating mantle. The solvent evaporated and passes through 
the side arm into the upper reflux condenser, then condensed into liquid and dripped to 
another round bottom flask placed at the other side. The process was continued until 
concentrated extract was collected, and then transferred into a sample bottle. The 
concentrated extract was left to dry through natural evaporation process until no traces 
of solvent smell were left. Solvent-extracted crude extract was placed in a desiccator or a 
fume cupboard.  
3.7 Screening for Anti-Quorum Sensing Activities of the Plant Samples 
3.7.1 C. violaceum CV026 Plate Assay 
 Overnight culture of C. violaceum CV026 cells (15 ml) were added into 200 ml 
of molten LB agar. Then,C6-HSL of 0.25 µg/ml was added into the LB agar that has 
been seeded with C. violaceum CV026 cells. Immediately after that, the C. violaceum 
CV026 agar suspension was poured into petri dishes and allowed to solidify for 30 min. 
Once the agar has solidified, wells were made on the agar by using sterile pipette tips. 
Then, 30 µl of plant extract was placed in the well and the plates were incubated for 24 h 
at 28 ˚C(Blosser & Gray, 2000). 
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3.7.2 C. violaceum CV026 Violacein Quantification Assay 
 The optical densityat 600 nm (OD600nm) of the overnight culture of C.violaceum 
CV026 was adjusted to 1.2 prior to be used. Den C6-HSL of 0.125 µg/ml was 
supplemented into the culture. In each well, approximately 90 µl of C. violaceum CV026 
cells was placed in it, followed by the addition of 10 µl of plant crude extract. Later, the 
96-well plate was placed in a shaking incubator of 28 ˚C. After incubation of 16 h, the 
treated cells were placed in a 60 ˚C oven with an open lid to allow evaporation of the 
LBB. Once the wells were dried completely, DMSO of 100 µl was placed into each 
well. Then, the 96-well plate was placed in a shaker until all the violacein was 
solubilized. The absorbance of each well was read at 590 nm using using DYNEX MRX 
Elisa reader (Chantilly, VA, USA)(Martinelli et al., 2004). 
3.7.3 Quantification of Bioluminescence from E. coli [pSB401] and E. coli 
[pSB1075] 
Bioluminescence expression was quantified using a 
Tecanluminometer(InfiniteM200,Mannerdorf,Switzerland). Briefly, overnight culture of 
E. coli biosensors cells was diluted to an OD600nm of 0.1. Then, 230 µl of E. coli 
biosensors cells and 20 µl of plant extract were added into the well of 96-well microtitre 
plate. The bioluminescence and OD495nm were determined every 30 min for 24 h by the 
luminometer. Expression of bioluminescence was given as relative light unit 
(RLU)/OD495nm against time(Winzer et al., 2000). 
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3.7.4 P. aeruginosa PA01 Pyocyanin Quantification Assay 
Overnight culture of P. aeruginosa PA01 was adjusted to an OD600nm of 0.2. Then, 
250 µl of plant extract was added and mixed well with P. aeruginosa PA01 cells (4.75 
ml) in a polypropylene tube and incubated at 37 ˚C for 24 h. The 5 ml culture was 
extracted with 3 ml of chloroform, followed by mixing the chloroform layer with 1 ml of 
0.2 M HCl. The absorbance of the pink extracted organic layer was then measured at 
520 nm (Essaret al., 1990). 
3.7.5 Quantification of P. aeruginosa PA01 lecA Expression 
P. aeruginosa PA01 lecA expression was quantified using a Tecanluminometer 
(Infinite M200,Mannerdorf, Switzerland). Briefly, overnight culture of P. aeruginosa 
PA01 lecA::lux was diluted to an OD600nm of 0.1. Then, 230 µl of P. aeruginosa PA01 
lecA::lux and20 µl of plant extract were added into the well of 96-well microtitre plate. 
The bioluminescence and OD495nm were determined every 30 min for 24 h by the 
luminometer. P. aeruginosa PA01 lecA::lux expression was given as 
RLU/OD495nmagainst time(Winzer et al., 2000). 
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3.7.6 P. aeruginosa PA01 Swarming Assay 
 Molten swarming agar (10 ml) was poured into the petri dish. The petri dish was 
then placed in the laminar flow for 30 min. Then, the solidified swarming agar was 
overlaid with 4.75 ml of molten swarming agar that has been supplemented with 250 µl 
of plant extract. The 15 ml thickness agar was then air blown for another 30 min in the 
laminar flow. Finally, overnight culture of P. aeruginosa PA01 of 2 µl was inoculated in 
the centre of the agar and incubated for 16 h at 37 ˚C.  
3.7.7 Statistical Tests 
All assays were performed on triplicate basis and the significance of the data was 
tested using ANOVA test (P< 0.05) using GraphPad Prism software (Version 5.00). 
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3.8 Fractionation of Active Plant Extract (Chloroform Extract of M. lunu-ankenda) 
using Agilent Preparative HPLC 
Fractionation of active crude extract was carried out using an Agilent 
Technologies 1260 Infinity Series HPLC system (Agilent Technologies, Germany) that 
consists of two preparative pumps, an autosampler, a diode-array detector (DAD) and a 
fraction collector. Crude extract to be fractionated was diluted with ACN before injected 
into the system. Sample of 1500 µl was injected into the HPLC system and was applied 
onto a C18 preparative cartridge (Agilent PrepHT XDB-C18, 21.2  mm × 250 mm, 7 µm 
particle size) with an attached guard column (Agilent ZORBAX XDB-C18, 5 µm 
particle size).The preparative system was run on an isocratic profile of ACN-water 
(30:70, v/v) for 40 min at a constant flow rate of 10 ml/min and the spectrum was 
monitored at 210 nm. Fractions were collected from the 4
th
 min till the 40
th
 min of the 
run (Table 3.2). 
Fractions collected were concentrated via rotary evaporator and once dried, 
fractions were weight 5 mg and dissolved in 0.5 ml of DMSO to prepare a 10 mg/ml 
sample stock solution which was then kept in a 1.5 ml microcentrifudge tube. The tube 
which contained the stock solution was mixed well by vortex machine. Once labeled, the 
sample tube was stored at -20˚C freezer for next usage. Prior to be used, the plants 
extract was diluted with sterile distilled water to desired concentration. The fractions 
were tested on swarming assay, P. aeruginosaPA01 lecA::lux and E. coli [pSB401] to 
determine which fraction contains active compounds. 
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Table 3.2: Collection time for the separated fractions. 
Time (min) Fractions 
4
th
- 5
th
 1 
5
th
- 6th 2 
6
th
- 7
th
 3 
7
th
- 8
th
 4 
8
th
- 9
th
 5 
9
th
- 10
th
 6 
10
th
- 11
th
 7 
11
th
- 12
th
 8 
12
th
 – 13th 9 
13
th
 – 18.5th 10 
18.5
th
 – 21st 11 
21
st
 – 23rd 12 
23
rd
 – 31st 13 
31
st
 – 40th 14 
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CHAPTER 4 
RESULTS 
 
4.1 Plant Samples Identification and Depositions of Voucher Specimens 
Plant samples that have been deposited in the Herbarium of University of Malaya 
were each given an identification number (Table 4.1). 
Table 4.1: List of plant samples and their respective voucher specimen number. 
Sample Voucher specimen number 
M. lunu-ankenda 047697 
P. betle 047696 
G. gnemon 047698 
P. nigrum 047695 
 
 
 
 
 
 
 
 
 
 
62 
 
4.2 C. violaceum CV026 Plate Assay 
 After incubation for 24 h, the data was documented using a camera. The C. 
violaceum CV026 lawn turned purple in the presence of exogenously supplied short 
chain AHLs. Plant extracts that caused formation of halo zone around the well signified 
that anti-QS compounds existed in the plant sample.  
In general, as the concentration of the extract increases, the size of the halo zone 
formed around the well increased as well. All of the plant extracts (Figure 4.1 and Figure 
4.2) showed halo zone formation except for the methanol extract of P. betle (Figure 4.1 
(f)), chloroform and methanol extracts of G. gnemon (Figure 4.2 (b) and (c)). The 
extracts which showed the most prominent formation of halo zone surrounded by purple 
violacein background were the chloroform and methanol extracts of P. nigrum(Figure 
4.2 (e) and (f)).  
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Figure 4.1: (a) M. lunu-ankenda-Hexane extract; (b) M. lunu-ankenda-
Chloroform extract; (c) M. lunu-ankenda-Methanol extract; (d) P. betle-Hexane extract; 
(e) P. betle-Chloroform extract; (f) P. betle-Methanol extract. 
 
 
(a) 
(b) 
(c) 
(d) 
(e) 
(f) 
1 2 3 4 5 mg/ml 
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Figure 4.2: (a) G. gnemon-Hexane extract; (b) G. gnemon-Chloroform extract; 
(c) G. gnemon-Methanol extract; (d) P. nigrum-Hexane extract; (e) P. nigrum-
Chloroform extract; (f) P. nigrum-Methanol extract. 
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4.3 C. violaceum CV026 Violacein Quantification Assay 
Violacein formed by C. violaceum CV026 was quantified by measuring the 
amount of violacein that has solubilized in the DMSO using DYNEX MRX Elisa reader 
(Chantilly, VA, USA). The triplicate results obtained were used to calculate the standard 
error as seen on the bar graphs (Figure 4.3 and 4.4). Extracts that caused significant 
reduction in violacein productions were M. lunu-ankenda chloroform (Figure 4.3 (b)) 
and methanol extracts (Figure 4.3 (c)) and all three extracts of P. betle (Figure 4.3 (d-f)) 
and P. nigrum (Figure 4.4 d-f).  
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Figure 4.3: (a) M. lunu-ankenda-Hexane extract; (b)M. lunu-ankenda-
Chloroform extract; (c) M. lunu-ankenda-Methanol extract; (d) P. betle-Hexane extract; 
(e) P. betle- Chloroform extract; (f) P. betle-Methanol extract. 
  
 
 
 
(a) (b) (c) 
(d) (e) (f) 
67 
 
D
M
SO
G
. g
ne
m
on
D
M
SO
G
. g
ne
m
on
D
M
SO
G
. g
ne
m
on
D
M
SO
G
. g
ne
m
on
0.0
0.2
0.4
0.6
1 mg/ml
2 mg/ml
3 mg/ml
4 mg/ml
V
io
la
c
e
in
 (
O
D
5
9
0
n
m
)
D
M
SO
G
. g
ne
m
on
D
M
SO
G
. g
ne
m
on
D
M
SO
G
. g
ne
m
on
D
M
SO
G
. g
ne
m
on
0.0
0.2
0.4
0.6
1 mg/ml
2 mg/ml
3 mg/ml
4 mg/ml
V
io
la
c
e
in
 (
O
D
5
9
0
n
m
)
D
M
SO
G
. g
ne
m
on
D
M
SO
G
. g
ne
m
on
D
M
SO
G
. g
ne
m
on
D
M
SO
G
. g
ne
m
on
0.0
0.2
0.4
0.6
1 mg/ml
2 mg/ml
3 mg/ml
4 mg/ml
V
io
la
c
e
in
 (
O
D
5
9
0
n
m
)
 
 
D
M
SO
P.
 n
ig
ru
m
D
M
SO
P.
 n
ig
ru
m
D
M
SO
P.
 n
ig
ru
m
D
M
SO
P.
 n
ig
ru
m
0.0
0.1
0.2
0.3
0.4
0.5
1 mg/ml
2 mg/ml
3 mg/ml
4 mg/ml
V
io
la
c
e
in
 (
O
D
5
9
0
n
m
)
D
M
SO
P.
 n
ig
ru
m
D
M
SO
P.
 n
ig
ru
m
D
M
SO
P.
 n
ig
ru
m
D
M
SO
P.
 n
ig
ru
m
0.0
0.1
0.2
0.3
0.4
0.5
1 mg/ml
2 mg/ml
3 mg/ml
4 mg/ml
V
io
la
c
e
in
 (
O
D
5
9
0
n
m
)
D
M
SO
P.
 n
ig
ru
m
D
M
SO
P.
 n
ig
ru
m
D
M
SO
P.
 n
ig
ru
m
D
M
SO
P.
 n
ig
ru
m
0.0
0.1
0.2
0.3
0.4
0.5
1 mg/ml
2 mg/ml
3 mg/ml
4 mg/ml
V
io
la
ce
in
 (
O
D
5
9
0
n
m
)
 
 
 
Figure 4.4: (a) G. gnemon-Hexane extract; (b) G. gnemon-Chloroform extract; 
(c) G. gnemon-Methanol extract; (d) P. nigrum-Hexane extract; (e) P. nigrum-
Chloroform extract; (f) P. nigrum-Methanol extract. 
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4.4 Quantification of Bioluminescence from E. coli [pSB401]  
 Bioluminescence of E. coli [pSB401] was quantified using a Tecan 
luminometer(InfiniteM200,Mannerdorf,Switzerland). Plant extracts that contain anti-QS 
compounds will cause the bioluminescence reading to be reduced significantly. The 
graphs drawn were based on triplicate reading and the error bars were shown on the 
graphs as well. Surprisingly, all of the extracts significantly inhibited the 
bioluminescence of E. coli [pSB401] (Figure 4.5- Figure 4.10). 
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Figure 4.5: (a) M. lunu-ankenda-Hexane extract (1 mg/ml); (b) M. lunu-ankenda-
Hexane extract (2 mg/ml); (c)M. lunu-ankenda-Hexane extract (3 mg/ml); (d) M. lunu-
ankenda-Chloroform extract (1 mg/ml); (e) M. lunu-ankenda-Chloroform extract (2 
mg/ml); (f)M. lunu-ankenda-Chloroform extract (3 mg/ml). 
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Figure 4.6: (a) M. lunu-ankenda-Methanol extract (1 mg/ml); (b) M. lunu-
ankenda-Methanol extract (2 mg/ml); (c)M. lunu-ankenda-Methanol extract (3 mg/ml); 
(d) P. betle-Hexane extract (1 mg/ml); (e) P. betle-Hexane extract (2 mg/ml); (f) P. 
betle-Hexane extract (3 mg/ml). 
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Figure 4.7: (a) P. betle-Chloroform extract (1 mg/ml); (b) P. betle-Chloroform 
extract (2 mg/ml); (c) P. betle-Chloroform extract (3 mg/ml); (d) P. betle-Methanol 
extract (1 mg/ml); (e) P. betle-Methanol extract (2 mg/ml); (f) P. betle-Methanol extract 
(3 mg/ml). 
 
 
 
(a) (b) 
(c) (d) 
(e) (f) 
72 
 
0 1 2 3 4 5 6 7 8 9101112131415161718192021222324
0.0
200000.0
400000.0
600000.0
800000.0
DMSO 10%
G. gnemon - 1 mg/ml
Time  (H)
R
L
U
/O
D
4
9
5
0 1 2 3 4 5 6 7 8 9101112131415161718192021222324
0
200000
400000
600000
DMSO 20%
G. gnemon - 2 mg/ml
Time  (H)
R
L
U
/O
D
4
9
5
 
0 1 2 3 4 5 6 7 8 9101112131415161718192021222324
0
100000
200000
300000
400000
DMSO 30%
G. gnemon - 3 mg/ml
Time  (H)
R
L
U
/O
D
4
9
5
0 1 2 3 4 5 6 7 8 9101112131415161718192021222324
0.0
200000.0
400000.0
600000.0
800000.0
DMSO 10%
G. gnemon - 1 mg/ml
Time  (H)
R
L
U
/O
D
4
9
5
 
 
0 1 2 3 4 5 6 7 8 9101112131415161718192021222324
0
200000
400000
600000
DMSO 20%
G. gnemon - 2 mg/ml
Time  (H)
R
L
U
/O
D
4
9
5
0 1 2 3 4 5 6 7 8 9101112131415161718192021222324
0
100000
200000
300000
400000
DMSO 30%
G. gnemon - 3 mg/ml
Time  (H)
R
L
U
/O
D
4
9
5
 
 
Figure 4.8: (a) G. gnemon-Hexane extract (1 mg/ml); (b) G. gnemon-Hexane 
extract (2 mg/ml); (c) G. gnemon-Hexane extract (3 mg/ml); (d) G. gnemon-Chloroform 
extract (1 mg/ml); (e) G. gnemon-Chloroform extract (2 mg/ml); (f) G. gnemon-
Chloroform extract (3 mg/ml). 
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Figure 4.9: (a) G. gnemon-Methanol extract (1 mg/ml); (b) G. gnemon-Methanol 
extract (2 mg/ml); (c) G. gnemon-Methanol extract (3 mg/ml); (d) P. nigrum-Hexane 
extract (1 mg/ml); (e) P. nigrum-Hexane extract (2 mg/ml); (f)P. nigrum-Hexane extract 
(3 mg/ml). 
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Figure 4.10: (a) P. nigrum-Chloroform extract (1 mg/ml); (b) P. nigrum-
Chloroform extract (2 mg/ml); (c)P. nigrum-Chloroform extract (3 mg/ml); (d) P. 
nigrum-Methanol extract (1 mg/ml); (e) P. nigrum-Methanol extract (2 mg/ml); (f)P. 
nigrum-Methanol extract (3 mg/ml). 
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4.5 Quantification of Bioluminescence from E. coli [pSB1075] 
 After 24 h, the readings were collected from the 
luminometer(InfiniteM200,Mannerdorf,Switzerland) and the graphs of RLU/OD495 
against time (h) were plotted. Hexane, chloroform and methanol extracts of each plant 
were tested against E. coli [pSB1075] in three concentrations namely 1, 2 and 3 mg/ml. 
Plant extracts that showed significance inhibition of bioluminescence from E. coli 
[pSB1075] were P. betle-Hexane extract (Figure 4.12 (d-f)), G. gnemon-Chloroform 
(Figure 4.14 (d-f)) and methanol extracts (Figure 4.15 (a-c)) while all the extracts of M. 
lunu-ankenda (Figure 4.11 and Figure 4.12 (a-c)), chloroform and methanol extracts of 
P. betle (Figure 4.13), hexane extract of G. gnemon (Figure 4.14 (a-c)) and all extracts 
of P. nigrum (Figure 4.15 (d-f) and Figure 4.16) did not showed any significant 
inhibition. 
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Figure 4.11: (a) M. lunu-ankenda-Hexane extract (1 mg/ml); (b) M. lunu-
ankenda-Hexane extract (2 mg/ml); (c)M. lunu-ankenda-Hexane extract (3 mg/ml); (d) 
M. lunu-ankenda-Chloroform extract (1 mg/ml); (e)M. lunu-ankenda-Chloroform extract 
(2 mg/ml); (f)M. lunu-ankenda-Chloroform extract (3 mg/ml). 
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Figure 4.12: (a) M. lunu-ankenda-Methanol extract (1 mg/ml); (b) M. lunu-
ankenda-Methanol extract (2 mg/ml); (c)M. lunu-ankenda-Methanol extract (3 mg/ml); 
(d) P. betle-Hexane extract (1 mg/ml); (e) P. betle-Hexane extract (2 mg/ml); (f) P. 
betle-Hexane extract (3 mg/ml). 
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Figure 4.13: (a) P. betle-Chloroform extract (1 mg/ml); (b) P. betle-Chloroform 
extract (2 mg/ml); (c) P. betle-Chloroform extract (3 mg/ml); (d) P. betle-Methanol 
extract (1 mg/ml); (e) P. betle-Methanol extract (2 mg/ml); (f) P. betle-Methanol extract 
(3 mg/ml). 
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Figure 4.14: (a) G. gnemon-Hexane extract (1 mg/ml); (b) G. gnemon-Hexane 
extract (2 mg/ml); (c) G. gnemon-Hexane extract (3 mg/ml); (d) G. gnemon-Chloroform 
extract (1 mg/ml); (e) G. gnemon-Chloroform extract (2 mg/ml); (f) G. gnemon-
Chloroform extract (3 mg/ml). 
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Figure 4.15: (a) G. gnemon-Methanol extract (1 mg/ml); (b) G. gnemon-
Methanol extract (2 mg/ml); (c) G. gnemon-Methanol extract (3 mg/ml); (d) P. nigrum-
Hexane extract (1 mg/ml); (e) P. nigrum-Hexane extract (2 mg/ml); (f)P. nigrum-
Hexane extract (3 mg/ml). 
 
 
(a) (b) 
(c) (d) 
(e) (f) 
81 
 
0 1 2 3 4 5 6 7 8 9101112131415161718192021222324
0
50000
100000
150000
DMSO 10%
P. nigrum
 - 1 mg/ml
Time  (H)
R
L
U
/O
D
4
9
5
0 1 2 3 4 5 6 7 8 9101112131415161718192021222324
0
20000
40000
60000
80000
DMSO 20%
P. nigrum
- 2 mg/ml
Time  (H)
R
L
U
/O
D
4
9
5
 
 
0 1 2 3 4 5 6 7 8 9101112131415161718192021222324
0
20000
40000
60000
DMSO 30%
P. nigrum
 - 3 mg/ml
Time  (H)
R
L
U
/O
D
49
5
0 1 2 3 4 5 6 7 8 9101112131415161718192021222324
0
50000
100000
150000
DMSO 10%
P. nigrum
- 1 mg/ml
Time  (H)
R
L
U
/O
D
4
9
5
 
 
0 1 2 3 4 5 6 7 8 9101112131415161718192021222324
0
20000
40000
60000
80000
DMSO 20%
P. nigrum
- 2 mg/ml
Time  (H)
R
L
U
/O
D
4
9
5
0 1 2 3 4 5 6 7 8 9101112131415161718192021222324
0
20000
40000
60000
DMSO 30%
P. nigrum
 - 3 mg/ml
Time  (H)
R
L
U
/O
D
4
9
5
 
 
Figure 4.16: (a) P. nigrum-Chloroform extract (1 mg/ml); (b) P. nigrum-
Chloroform extract (2 mg/ml); (c)P. nigrum-Chloroform extract (3 mg/ml); (d) P. 
nigrum-Methanol extract (1 mg/ml); (e) P. nigrum-Methanol extract (2 mg/ml); (f)P. 
nigrum-Methanol extract (3 mg/ml). 
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4.6 P. aeruginosa PA01 Pyocyanin Quantification Assay 
 Pyocyanin extracted was quantified using a spectrophotometer (UV1601, 
Shidmazu, Kyoto, Japan)at 520 nm. It was found that all the extracts of M. lunu-ankenda 
(Figure 4.17 (a-c)) and P. betle (Figure 4.17 d-f)) showed significant inhibition against 
pyocyanin production. Chloroform extract of G. gnemon (Figure 4.18 (b)) was the only 
extract of G. gnemon that inhibited pyocyanin synthesis of P. aeruginosa PA01 
significantly. On the other hand, extracts that did not showed any significant inhibition 
against pyocyanin production were the hexane and methanol extract of G. gnemon 
(Figure 4.18 (a) and (c)) and all extracts of P. nigrum (Figure 4.18 (d-f)). 
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Figure 4.17: (a) M. lunu-ankenda-Hexane extract; (b) M. lunu-ankenda-
Chloroform extract; (c) M. lunu-ankenda-Methanol extract; (d) P. betle-Hexane extract; 
(e) P. betle- Chloroform extract; (f) P. betle- Methanol extract. 
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Figure 4.18: (a) G. gnemon-Hexane extract; (b) G. gnemon-Chloroform extract; 
(c) G. gnemon-Methanol extract; (d) P. nigrum-Hexane extract; (e) P. nigrum-
Chloroform extract; (f) P. nigrum-Methanol extract. 
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4.7 Quantification of P. aeruginosa PA01 lecA Expression 
 Quantification of the lecA expression of P. aeruginosa PA01 was enabled using 
a luminometer (InfiniteM200,Mannerdorf,Switzerland)that detects bioluminescence due 
to the construction of P. aeruginosa PA01 lecA::lux. Similar to the bioluminescence 
assay of E. coli [pSB401] and E. coli [pSB1075], hexane, chloroform and methanol 
extracts of M. lunu-ankenda(Figure 4.19 (a-f) and Figure 4.20 (a-c)), P. betle(Figure 
4.20 (d-f) and Figure 4.21 (a-f)), G. gnemon(Figure 4.22 (a-f) and Figure 4.23 (a-c)) and 
P. nigrum(Figure 4.23 (d-f) and Figure 4.24 (a-f)) were tested against P. aeruginosa 
PA01 lecA::luxat three ascending concentration, namely 1, 2 and 3 mg/ml. Of the 12 
extracts, the chloroform and methanol extracts of P. betle (Figure 4.21 (a-f)) and 
chloroform extracts of G. gnemon (Figure 4.22 (d-f)) significantly reduced lecA 
expression of P. aeruginosaPA01 lecA::lux.  
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Figure 4.19: (a) M. lunu-ankenda-Hexane extract (1 mg/ml);  (b) M. lunu-
ankenda-Hexane extract (2 mg/ml); (c)M. lunu-ankenda-Hexane extract (3 mg/ml); (d) 
M. lunu-ankenda-Chloroform extract (1 mg/ml); (e) M. lunu-ankenda-Chloroform 
extract (2 mg/ml); (f)M. lunu-ankenda-Chloroform extract (3 mg/ml). 
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Figure 4.20: (a) M. lunu-ankenda-Methanol extract (1 mg/ml);  (b) M. lunu-
ankenda-Methanol extract (2 mg/ml); (c)M. lunu-ankenda-Methanol extract (3 mg/ml); 
(d) P. betle-Hexane extract (1 mg/ml); (e) P. betle-Hexane extract (2 mg/ml); (f)P. betle-
Hexane extract (3 mg/ml). 
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Figure 4.21: (a) P. betle-Chloroform extract (1 mg/ml); (b) P. betle- Chloroform 
extract (2 mg/ml); (c) P. betle-Chloroform extract (3 mg/ml); (d) P. betle-Methanol 
extract (1 mg/ml); (e) P. betle- Methanol extract (2 mg/ml); (f) P. betle-Methanol extract 
(3 mg/ml). 
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Figure 4.22: (a) G. gnemon-Hexane extract (1 mg/ml); (b) G. gnemon-Hexane 
extract (2 mg/ml); (c) G. gnemon-Hexane extract (3 mg/ml); (d) G. gnemon-Chloroform 
extract (1 mg/ml); (e) G. gnemon-Chloroform extract (2 mg/ml); (f) G. gnemon-
Chloroform extract (3 mg/ml). 
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Figure 4.23: (a) G. gnemon-Methanol extract (1 mg/ml); (b) G. gnemon- 
Methanol extract (2 mg/ml); (c) G. gnemon-Methanol extract (3 mg/ml); (d) P. nigrum-
Hexane extract (1 mg/ml); (e) P. nigrum- Hexane extract (2 mg/ml); (f)P. nigrum- 
Hexane extract (3 mg/ml). 
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Figure 4.24: (a) P. nigrum- Chloroform extract (1 mg/ml); (b) P. nigrum- 
Chloroform extract (2 mg/ml); (c)P. nigrum-Chloroform extract (3 mg/ml); (d) P. 
nigrum-Methanol extract (1 mg/ml); (e) P. nigrum-Methanol extract (2 mg/ml); (f)P. 
nigrum-Methanol extract (3 mg/ml). 
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4.8 P. aeruginosa PA01 Swarming Assay 
 P. aeruginosa PA01 that has been loaded onto the control plate (without addition 
of plant extracts) swarmed until the edge of the plate after 16 h of incubation. Hexane, 
chloroform and methanol extract of M. lunu-ankenda (Figure 4.25), P. betle (Figure 
4.26), G. gnemon (Figure 4.27) and P. nigrum (Figure 4.28) were seeded into the 
swarming agar and the extent of swarming inhibition exerted by these extracts was 
compared with the control plate. M. lunu-ankenda-Chloroform (Figure 4.25 (f-h)) and P. 
betle-Methanol (Figure 4.26 (i-k)) extracts display observable inhibition against 
swarming motility of P. aeruginosa PA01. Agar that has been seeded with these two 
extracts has successfully inhibited the swarming motility of P. aeruginosa PA01 as the 
bacteria did not swarm until the edge of the plate and just formed a smaller protrusion 
from its original position as compared with other plant extracts. 
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Figure 4.25: Swarming agars of (a) P. aeruginosa PA01that has been 
supplemented with (b) DMSO 30% (v/v, negative control);M. lunu-ankenda-Hexane 
extracts of (c) 1 mg/ml, (d) 2 mg/ml and (e) 3 mg/ml; M. lunu-ankenda-Chloroform 
extracts of (f) 1 mg/ml, (g) 2 mg/ml and (h) 3 mg/ml; and M. lunu-ankenda-Methanol 
extracts of (i) 1 mg/ml, (j) 2 mg/ml and (k) 3 mg/ml. 
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Figure 4.26: Swarming agars of (a) P. aeruginosa PA01that has been 
supplemented with (b) DMSO 30% (v/v, negative control);P. betle-Hexane extracts of 
(c) 1 mg/ml, (d) 2 mg/ml and (e) 3 mg/ml; P. betle-Chloroform extracts of (f) 1 mg/ml, 
(g) 2 mg/ml and (h) 3 mg/ml; and P. betle-Methanol extracts of (i) 1 mg/ml, (j) 2 mg/ml 
and (k) 3 mg/ml. 
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Figure 4.27: Swarming agars of (a) P. aeruginosa PA01that has been 
supplemented with (b) DMSO 30% (v/v, negative control); G. gnemon-Hexane extracts 
of (c) 1 mg/ml, (d) 2 mg/ml and (e) 3 mg/ml; G. gnemon-Chloroform extracts of (f) 1 
mg/ml, (g) 2 mg/ml and (h) 3 mg/ml; and G. gnemon-Methanol extracts of (i) 1 mg/ml, 
(j) 2 mg/ml and (k) 3 mg/ml. 
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Figure 4.28: Swarming agars of (a) P. aeruginosa PA01that has been 
supplemented with (b) DMSO 30% (v/v, negative control); P. nigrum-Hexane extracts 
of (c) 1 mg/ml, (d) 2 mg/ml and (e) 3 mg/ml; P. nigrum-Chloroform extracts of (f) 1 
mg/ml, (g) 2 mg/ml and (h) 3 mg/ml; and P. nigrum-Methanol extracts of (i) 1 mg/ml, 
(j) 2 mg/ml and (k) 3 mg/ml. 
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4.9 Fractions Collected from M. lunu-ankenda Chloroform Extract 
A total of 14 fractions were collected over the course of 40 min at 210 nm 
(Figure 4.29). No collection was made from minute 0-4 as no peak was observed.
 
Figure 4.29: Chromatogram of M. lunu-ankenda chloroform extract after 40 min. 
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4.10 Bioluminescence Assay of P. aeruginosaPA01 lecA::lux on Fractions of M. 
lunu-ankenda Chloroform Extract 
The fractions collected from M. lunu-ankenda were tested against P. aeruginosa 
PA01 lecA::lux at three concentrations, namely 0.5 mg/ml, 1.0 mg/ml and 1.5 mg/ml 
(Figure 4.30- Figure 4.36). None of the fraction of M. lunu-ankendashowed significant 
inhibition against P. aeruginosa PA01 lecA::lux.  
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Figure 4.30: (a) Fraction 1 (0.5 mg/ml); (b) Fraction 1 (1.0 mg/ml); (c) Fraction 1 
(1.5 mg/ml); (d) Fraction 2 (0.5 mg/ml); (e) Fraction 2 (1.0 mg/ml); (f) Fraction 2 (1.5 
mg/ml). 
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Figure 4.31: (a) Fraction 3 (0.5 mg/ml); (b) Fraction 3 (1.0 mg/ml); (c) Fraction 3 
(1.5 mg/ml); (d) Fraction 4 (0.5 mg/ml); (e) Fraction 4 (1.0 mg/ml); (f) Fraction 4 (1.5 
mg/ml). 
 
 
 
 
(a) 
(f) (e) 
(d) (c) 
(b) 
101 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.32: (a) Fraction 5 (0.5 mg/ml); (b) Fraction 5 (1.0 mg/ml); (c) Fraction 5 
(1.5 mg/ml); (d) Fraction 6 (0.5 mg/ml); (e) Fraction 6 (1.0 mg/ml); (f) Fraction 6 (1.5 
mg/ml). 
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Figure 4.33: (a) Fraction 7 (0.5 mg/ml); (b) Fraction 7 (1.0 mg/ml); (c) Fraction 7 
(1.5 mg/ml); (d) Fraction 8 (0.5 mg/ml); (e) Fraction 8 (1.0 mg/ml); (f) Fraction 8 (1.5 
mg/ml). 
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Figure 4.34: (a) Fraction 9 (0.5 mg/ml); (b) Fraction 9 (1.0 mg/ml); (c) Fraction 9 
(1.5 mg/ml); (d) Fraction 10 (0.5 mg/ml); (e) Fraction 10 (1.0 mg/ml); (f) Fraction 10 
(1.5 mg/ml). 
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Figure 4.35: (a) Fraction 11 (0.5 mg/ml); (b) Fraction 11 (1.0 mg/ml); (c) 
Fraction 11 (1.5 mg/ml); (d) Fraction 12 (0.5 mg/ml); (e) Fraction 12 (1.0 mg/ml); (f) 
Fraction 12 (1.5 mg/ml). 
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Figure 4.36: (a) Fraction 13 (0.5 mg/ml); (b) Fraction 13 (1.0 mg/ml); (c) 
Fraction 13 (1.5 mg/ml); (d) Fraction 14 (0.5 mg/ml); (e) Fraction 14 (1.0 mg/ml); (f) 
Fraction 14 (1.5 mg/ml). 
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4.11 Bioluminescence Assay of E. coli [pSB401] on Fractions of M. lunu-ankenda 
Chloroform Extract 
 Of the 14 fractions of M. lunu-ankenda(Figure 4.37- Figure 4.43) that has been 
tested against E. coli [pSB401], only Fraction 4 at 1.5 mg/ml (Figure 4.38 (f)), Fraction 
11 at 1.0 mg/ml and 1.5 mg/ml (Figure 4.42 (b) and (c)), Fraction 12 at 1.5 mg/ml 
(Figure 4.42 (f)), Fraction 13 at all concentrations (Figure 4.43 (a-c)) and Fraction 14 at 
1.5 mg/ml (Figure 4.43 (f)) gave significant inhibition.  
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Figure 4.37: (a) Fraction 1 (0.5 mg/ml); (b) Fraction 1 (1.0 mg/ml); (c) Fraction 1 
(1.5 mg/ml); (d) Fraction 2 (0.5 mg/ml); (e) Fraction 2 (1.0 mg/ml); (f) Fraction 2 (1.5 
mg/ml). 
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Figure 4.38: (a) Fraction 3 (0.5 mg/ml); (b) Fraction 3 (1.0 mg/ml); (c) Fraction 3 
(1.5 mg/ml); (d) Fraction 4 (0.5 mg/ml); (e) Fraction 4 (1.0 mg/ml); (f) Fraction 4 (1.5 
mg/ml). 
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Figure 4.39: (a) Fraction 5 (0.5 mg/ml); (b) Fraction 5 (1.0 mg/ml); (c) Fraction 5 
(1.5 mg/ml); (d) Fraction 6 (0.5 mg/ml); (e) Fraction 6 (1.0 mg/ml); (f) Fraction 6 (1.5 
mg/ml). 
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Figure 4.40: (a) Fraction 7 (0.5 mg/ml); (b) Fraction 7 (1.0 mg/ml); (c) Fraction 7 
(1.5 mg/ml); (d) Fraction 8 (0.5 mg/ml); (e) Fraction 8 (1.0 mg/ml); (f) Fraction 8 (1.5 
mg/ml). 
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Figure 4.41: (a) Fraction 9 (0.5 mg/ml); (b) Fraction 9 (1.0 mg/ml); (c) Fraction 9 
(1.5 mg/ml); (d) Fraction 10 (0.5 mg/ml); (e) Fraction 10 (1.0 mg/ml); (f) Fraction 10 
(1.5 mg/ml). 
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Figure 4.42: (a) Fraction 11 (0.5 mg/ml); (b) Fraction 11 (1.0 mg/ml); (c) 
Fraction 11 (1.5 mg/ml); (d) Fraction 12 (0.5 mg/ml); (e) Fraction 12 (1.0 mg/ml); (f) 
Fraction 12 (1.5 mg/ml). 
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Figure 4.43: (a) Fraction 13 (0.5 mg/ml); (b) Fraction 13 (1.0 mg/ml); (c) 
Fraction 13 (1.5 mg/ml); (d) Fraction 14 (0.5 mg/ml); (e) Fraction 14 (1.0 mg/ml); (f) 
Fraction 14 (1.5 mg/ml). 
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4.12 Anti-Swarming Properties of Fractions of M. lunu-ankenda Chloroform 
Extract 
 Of the 14 fractions of M. lunu-ankendachloroform extracts (Figure 4.44-Figure 
4.48), only two fractions showed significant inhibition. Fraction 5 (Figure 4.45 (f-h)) 
and Fraction 11 (Figure 4.47 (f-h)) significantly inhibited the swarming motility of P. 
aeruginosa PA01 because at 0.5 mg/ml, there was no observable swarming of the 
bacteria.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
115 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.44: Swarming agars of (a) P. aeruginosa PA01that has been 
supplemented with (b) DMSO 15 % (v/v, negative control);M. lunu-ankenda-
Chloroform extracts of Fraction 1 (c) 0.5 mg/ml, (d) 1 mg/ml and (e) 1.5 mg/ml; 
Fraction 2 (f) 0.5 mg/ml, (g) 1 mg/ml and (h) 1.5 mg/ml; and Fraction 3 (i) 0.5 mg/ml, 
(j) 1 mg/ml and (k) 1.5 mg/ml. 
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Figure 4.45: Swarming agars of (a) P. aeruginosa PA01that has been 
supplemented with (b) DMSO 15 % (v/v, negative control);M. lunu-ankenda-
Chloroform extracts of Fraction 4 (c) 0.5 mg/ml, (d) 1.0 mg/ml and (e) 1.5 
mg/ml;Fraction 5 (f) 0.5 mg/ml, (g) 1 mg/ml and (h) 1.5 mg/ml; and Fraction 6 (i) 0.5 
mg/ml, (j) 1 mg/ml and (k) 1.5 mg/ml. 
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Figure 4.46: Swarming agars of (a) P. aeruginosa PA01that has been 
supplemented with (b) DMSO 15 % (v/v, negative control); M. lunu-ankenda-
Chloroform extracts of Fraction 7 (c) 0.5 mg/ml, (d) 1.0 mg/ml and (e) 1.5 
mg/ml;Fraction 8 (f) 0.5 mg/ml, (g) 1 mg/ml and (h) 1.5 mg/ml; and Fraction 9 (i) 0.5 
mg/ml, (j) 1 mg/ml and (k) 1.5 mg/ml. 
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Figure 4.47: Swarming agars of (a) P. aeruginosa PA01that has been 
supplemented with (b) DMSO 15 % (v/v, negative control);M. lunu-ankenda-
Chloroform extracts of Fraction 10 (c) 0.5 mg/ml, (d) 1.0 mg/ml and (e) 1.5 mg/ml; 
Fraction 11 (f) 0.5 mg/ml, (g) 1 mg/ml and (h) 1.5 mg/ml; and Fraction 12 (i) 0.5 mg/ml, 
(j) 1 mg/ml and (k) 1.5 mg/ml. 
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Figure 4.48: Swarming agars of (a) P. aeruginosa PA01that has been 
supplemented with (b) DMSO 15 % (v/v, negative control);M. lunu-ankenda-
Chloroform extracts of Fraction 13 (c) 0.5 mg/ml, (d) 1.0 mg/ml and (e) 1.5 mg/ml; and 
Fraction 14 (f) 0.5 mg/ml, (g) 1 mg/ml and (h) 1.5 mg/ml. 
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4.13 Summary of the Assays and Results Obtained  
 Data collected from M. lunu-ankenda, P. nigrum, P. betle and G. gnemon on the 
seven assays were summarized in Table 4.2 and 4.3, while Table 4.4 is the summary of 
the data collected from the 14 fractions of M. lunu-ankenda-Chloroform extract. 
 
Table 4.2: Summary of all the assays and results that has been collected from M. 
lunu-ankenda and P.nigrum.(√)indicatesthattheplantextracthasanti-
QSpropertieswhileplantextractswith (-) has no significant inhibition against QS.  
Assays M. lunu-
ankenda- 
Hexane 
M. lunu-
ankenda- 
Chlorofo
rm 
M. lunu-
ankenda- 
Methano
l 
P. 
nigrum- 
Hexane 
P. nigrum- 
Chlorofor
m 
P. nigrum- 
Methanol 
C. violaceum 
CV026 plate 
assay 
√ √ √ √ √ √ 
C. violaceum 
CV026 
violacein 
quantification 
assay 
- √ √ √ √ √ 
E. coli[pSB401] 
bioluminescence 
quantification 
assay 
√ √ √ √ √ √ 
E. 
coli[pSB1075] 
bioluminescence 
quantification 
assay 
- - - - - - 
P. aeruginosa 
PA01 pyocyanin 
quantification 
assay 
√ √ √ - - - 
P. aeruginosa 
PA01 lecA 
expression 
quantification 
- - - - - - 
P. aeruginosa 
PA01 swarming 
assay 
- √ - - - - 
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Table 4.3: Summary of all the assays and results that has been collected from P. 
betle and G. gnemon.(√)indicatesthattheplantextracthasanti-
QSpropertieswhileplantextractswith (-) has no significant inhibition against QS.  
Assays P. 
betle- 
Hexane 
P. betle- 
Chlorofor
m 
P. betle- 
Methanol 
G.gnemon
- Hexane 
G.gnemon- 
Chloroform 
G.gnemon
- Methanol 
C. violaceum 
CV026 plate 
assay 
√ √ - √ - - 
C. violaceum 
CV026 
violacein 
quantification 
assay 
√ √ √ - - - 
E. coli[pSB401] 
bioluminescence 
quantification 
assay 
√ √ √ √ √ √ 
E. 
coli[pSB1075] 
bioluminescence 
quantification 
assay 
√ - - - √ √ 
P. aeruginosa 
PA01 pyocyanin 
quantification 
assay 
√ √ √ - √ - 
P. aeruginosa 
PA01 lecA 
expression 
quantification 
- √ √ - √ - 
P. aeruginosa 
PA01 swarming 
assay 
- - √ - - - 
 
 
 
Table 4.4: Summary of all the assays and results that has been collected from M. 
lunu-ankenda- Chloroform extract fractions. (√)indicatesthattheplantextracthasanti-
QSpropertieswhileplantextractswith (-) has no significant inhibition against QS.  
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Fractions E. coli [pSB401] 
bioluminescence 
quantification assay 
P. aeruginosa PA01 
lecA expression 
quantification 
P. aeruginosa PA01 
swarming assay 
1 (0.5 mg/ml) - - - 
1 (1.0 mg/ml) - - - 
1 (1.5 mg/ml) - - - 
2 (0.5 mg/ml) - - - 
2 (1.0 mg/ml) - - - 
2 (1.5 mg/ml) - - - 
3 (0.5 mg/ml) - - - 
3 (1.0 mg/ml) - - - 
3 (1.5 mg/ml) - - - 
4 (0.5 mg/ml) - - - 
4 (1.0 mg/ml) - - - 
4 (1.5 mg/ml) √ - - 
5 (0.5 mg/ml) - - √ 
5 (1.0 mg/ml) - - √ 
5 (1.5 mg/ml) - - √ 
6 (0.5 mg/ml) - - - 
6 (1.0 mg/ml) - - - 
6 (1.5 mg/ml) - - - 
7 (0.5 mg/ml) - - - 
7 (1.0 mg/ml) - - - 
7 (1.5 mg/ml) - - - 
8 (0.5 mg/ml) - - - 
8 (1.0 mg/ml) - - - 
8 (1.5 mg/ml) - - - 
 
Table 4.4, continued. 
9 (0.5 mg/ml) - - - 
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9 (1.0 mg/ml) - - - 
9 (1.5 mg/ml) - - - 
10 (0.5 mg/ml) - - - 
10 (1.0 mg/ml) - - - 
10 (1.5 mg/ml) - - - 
11 (0.5 mg/ml) - - √ 
11 (1.0 mg/ml) √ - √ 
11 (1.5 mg/ml) √ - √ 
12 (0.5 mg/ml) - - - 
12 (1.0 mg/ml) - - - 
12 (1.5 mg/ml) √ - - 
13 (0.5 mg/ml) √ - - 
13 (1.0 mg/ml) √ - - 
13 (1.5 mg/ml) √ - - 
14 (0.5 mg/ml) - - - 
14 (1.0 mg/ml) - - - 
14 (1.5 mg/ml) √ - - 
 
 
 
 
 
 
CHAPTER 5 
124 
 
DISCUSSIONS 
5.1 Identification of Plant Samples and Preparation of Plant Crude Extracts 
The plant samples that had been purchased were identified by the curator of the 
University of Malaya Herbarium in order to obtain the accurate genus and species name 
for each sample. Voucher specimens (Figure 2.3-Figure 2.6) that had been deposited into 
the Herbarium can be searched easily thru the identification numbers (Table 4.1) given 
to each specimen.  
The technique used for sample extraction in this study is known as infusion.  
Three solvents with different degree of polarity were used to extract various secondary 
metabolites from M. lunu-ankenda, P. betle, G. gnemon and P. nigrum. Methanol is the 
most polar solvent used in this study followed by chloroform with intermediated polarity 
and the least polar of the three solvents used is hexane. Types of compound commonly 
extracted by hexane includes waxes, fats, fixed oils and volatile oils while for 
chloroform, it includes alkaloids, aglycones and volatile oils. Sugars, amino acids and 
glycosides can be extracted by methanol(Houghton & Raman, 1998). 
M. lunu-ankenda, P. betle, G. gnemon and P. nigrum were known to contain 
essential oils (volatile oils) (Berry, 1980; Garg & Jain, 1992; Johnson et al., 2010; 
Sumathykutty et al,, 1999). A popular method to obtain volatile oils is the steam 
distillation method. There are several ways to execute steam distillation processes, for 
example by mixing the plant material with water and then heat it to boiling point 
(distillation with water). The vapours will be collected and once condensation occurs, 
the oil will be separated from the water. Though the steam distillation method requires 
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relatively simple equipment and no filtration step is needed to separate the oil from the 
plant material, it is not suitable to be use in the case where the extracted compounds 
contains heat sensitive or easily oxidized components (Houghton & Raman, 1998). 
Therefore, hexane is used in this study to extract the non-polar compounds.   
The plant samples obtained were washed to remove any foreign particle and soil 
before being placed in the oven for drying. The purpose of washing is to ensure that 
these particles do not cause any contamination. The drying oven has been set to 45 ˚C as 
this is the optimum temperature for efficient plant drying and at the same time, will not 
cause protein components of the plant to undergo denaturation. Solvents with different 
polarity were used in this study so that secondary metabolites with varying polarity can 
be obtained. After submerging the plant materials in the solvents, the materials were 
filtered and filtrate obtained was subjected to rotary evaporation. This is to ensure that 
all of the solvents are totally eliminated from the crude extract in the end. Besides that, 
total elimination of extraction solvents will also ensure that any bioactivity tested is not 
influence by the solvents.  
Plants crude extract stocks were prepared by dissolving the extract in DMSO. 
DMSO is usually used to solubilize poorly soluble drugs in permeation assays. One of 
the advantages of using DMSO is that it helps to remove the possibility of microbial 
contamination in the crude extract. Besides that, the ability of DMSO to solubilize a 
wide range of compounds is also the reason why it was chosen to dissolve the crude 
extracts (Dimethyl Sulphoxide (DMSO), a Dipolar Aprotic Reaction Solvent, 2007). 
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5.2 Anti-Qs Activity of M. lunu-ankenda, P. betle, G. gnemon and P. nigrum Crude 
Extracts 
 Malaysia biodiversity is rich with many local plants that have yet to be tested for 
their anti-QS properties. The plant samples used in this study are available locally. M. 
lunu-ankenda, P. betle and G. gnemonleaves can be bought fresh from the market while 
the seeds of P. nigrum were obtained in dried form. The main reason these plants were 
selected for this study is that as of to date, no anti-QS activity by these four plants 
against E. coli [pSB401], E. coli [pSB1075], C. violaceum CV026, P. aeruginosa PA01 
and P. aeruginosa PA01 lecA::lux were reported although their medicinal values have 
been published (Johnson et al., 2010; Pamar et al., 1997; Milton et al., 2012; Dasgupta 
& De, 2004; IIliya et al., 2003). The leaves of M. lunu-ankenda and G. gnemonare 
consumed by the locals as salad while the P. betle leaves are one of the ingredients 
found in betle quid. Peppercorns of P. nigrum are used as spices in many local cooking. 
M. lunu-ankenda, P. betle, G. gnemon and P. nigrumare also traditionally used to treat 
hypertension, bad breath, asthma and stomach discomfort respectively.  
M. lunu-ankenda, P. betle, G. gnemon and P. nigrum crude extracts has shown 
significant inhibition in the anti-QS assays performed in this study. To our knowledge, 
this is the first report of anti-QS activities from these plants. Data collected from this 
study showed that the crude extracts of M. lunu-ankenda significantly inhibited 
bioluminescence production by E. coli [pSB401], violacein formation by C. violaceum 
CV026, pyocyanin and swarming motility of P. aeruginosa PA01 while the extracts of 
P. betle showed similar assays inhibition with the addition of inhibiting the QS activities 
from E. coli [pSB1075] and P. aeruginosa PA01 lecA::lux. On the other hand, G. 
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gnemon has anti-QS activities against E. coli [pSB401], E. coli [pSB1075], pyocyanin 
production by P. aeruginosa PA01 and P. aeruginosa PA01 lecA::lux. P. nigrum crude 
extracts only inhibits QS activities by E. coli [pSB401] and C. violaceum CV026.  
C. violaceum,a Gram negative bacterium that was first reported as a pathological 
strain when studies showed that this bacterium is the cause of infections in fetal water 
buffaloes in the Philippines (Duran & Menck, 2001). C. violaceum is commonly found 
in soil and water, particularly in the tropical and subtropical areas(Teoh et al., 2006). C. 
violaceum synthesizes the purple pigment violacein, a QS-mediated trait regulated by 
C6-HSL. C. violaceum CV026, on the other hand, is a transposon mutant strain of C. 
violaceum that is unable to synthesize C6-HSL. Thus, C. violaceum CV026 can only 
produce violacein in the presence of exogenously supplied short chain AHLs (Chooet 
al., 2006; McClean et al., 1997).Violacein is a strong antioxidant and acts by protecting 
the bacteria membrane against oxidative stress (Konzen et al., 2006). 
In C. violaceum CV026 plate assay, formation of halo zone indicated that the 
plant samples is either inhibiting the C6-HSL competitively from binding to its 
transcriptional regulator, cviR; degrading the C6-HSL enzymatically, or removing the 
C6-HSL via active transport (Bauer & Teplitski, 2000; Dong et al., 2000; Leadbetter & 
Greenberg, 2000). All of the crude extracts with the exception of P. betle methanol 
extract, G. gnemon chloroform and methanol extracts have halo formation on the 
violacein background. The halo, white zone formed was opaque and not transparent 
indicating that the inhibition formed around the well was caused by QS inhibition and 
not due to inhibition of bacterial cell growth. In agreement to this finding, other plant 
extracts such as vanilla, T. fuciformis, Conocarpus erectus, Quercus virgiana and pea 
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seedlings have been found to possess anti-QS activity against bioreporter strain C. 
violaceum CV026. (Adonizio et al., 2006; Bauer & Teplitski, 2000; Choo et al., 2006; 
Teplitski et al., 2000; Zhu & Sun, 2008). 
The extracts that give the most prominent halo zone formation are the P. nigrum 
chloroform (Figure 4.2 (e)) and P. nigrummethanol (Figure 4.2 (f)) extracts. This was 
further verified by the violacein quantified after 16 h of incubation in 28 ⁰C. 
Quantification of the violacein gives a better picture of the extent of inhibition by the 
plant extracts. Violacein in P. nigrum chloroform extracts dropped to 0.108 at 4 mg/ml 
while the control gave a value of 0.359 (Figure 4.4 (e)) and the extent of violacein 
reduction is approximately 70 %. Ocimum sanctum, Manilkara zapota, Musa 
paradiciaca and Ananas comosusseems to be a better QS inhibitor for violacein 
formation by C. violaceum CV026 as these plant extracts caused 94.98 %, 90.28 %, 
89.54 % and 89.22 % reduction in violacein formation respectively in a study conducted 
by Musthafa and colleagues(Musthafa et al., 2010). Besides plants, fungal extracts can 
also inhibit violacein production in C. violaceum CV026. The medicinal mushroom, 
Phellinus igniarius has a special life cycle which requires it to produce bioactive 
compounds throughout its growth and metabolism. The freeze-dried mushroom was 
found to be inhibiting violacein production in C. violaceum CV026 after violacein 
quantification and measurement by the microplate reader (Zhu et al., 2012). 
E. coli [pSB1075] (with the lasR receptor) produces optimum luminescence in 
the presence of exogenous 3-OC12-HSL while E. coli [pSB401] (with the luxR receptor) 
respond well to 3-OC6-HSL. Both of these biosensors were initially constructed to ease 
the identification of the AHLs signal produced by other bacteria using methods such as 
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cross streaking or conditioned medium assays. E. coli [pSB1075] was constructed 
through the fusion of P. aeruginosalasRI regulatory region to the P. 
luminescens luxCDABEregion while for E. coli [pSB401], its construction involves the 
fusion of luxRluxI region of V. fischeri with the P. luminescens luxCDABEregion 
(Winson et al., 1998). The assay was then modified to suit the need of this study by 
quantitating the extend of bioluminescence produced at the end of the 24 h cycle in the 
Tecan luminometer. The positive control well consist of the biosensor with the addition of 
exogenous AHLs while the treated well contains biosensor, AHLs and plants extracts. The 
bioluminescence quantitated from the positive controlled well will be compared with the 
treated well. The results obtained from M. lunu-ankenda, P. betle, G. gnemon and P. 
nigrum crude extracts showed that all of the extracts significantly inhibited E. coli 
[pSB401] (Figure 4.5-Figure 4.10) whileP. betle-Hexane extract (Figure 4.12 (d-f)), G. 
gnemon-Chloroform (Figure 4.14 (d-f)) and Methanol extracts (Figure 4.15 (a-c)) 
inhibited E. coli [1075]. By screening the crude extracts with these biosensors, it gives a 
better picture on which type of QS system (long or short chain AHLs) that can be 
inhibited by the plant samples. Data collected from this study could suggest that the 
plant extracts may interrupt QS that depends on short chain AHLs more efficiently as 
compared to QS system that produce long chain AHLs.  
Similarly, clove (Syzygium aromaticum), a type Ayurveda spice which was 
traditionally used for treatment of asthma and allergies was extracted with a series of 
solvents. The chloroform and methanol extracts was found to be significantly inhibiting 
bioluminescence production of E. coli [1075]. Besides using E. coli [pSB401] and E. 
coli [1075] that has lux-based nature for screening, fluorescence-based biosensors can 
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also be used for the same purpose. Pseudomonas putida F117 (pKR-C12) was used for 
detection of long chain AHLs while E. coli MT102 (pJBA 132) was used for the 
detection of short chain AHLs in a study conducted to evaluate the anti-QS properties of 
essential oils from Colombian plants. The results obtain from this study showed that 
Lippia alba possess promising inhibitory against E. coli MT102 (pJBA 132) (Jaramillo-
Colorado et al., 2012; Krishnan et al., 2012). 
Pyocyanin, an exoproduct of P. aeruginosa PA01 was extracted and quantitated 
after cultured with plant crude extracts for 24 h. Data collected from this study showed 
that indeed Malaysian local plants have anti-QS properties. The assay was conducted 
based on the absorbance of pyocyanin in acidic medium at 520 nm. Generally, 
pyocyanin can be found in great quantity in the sputum of cystic fibrosis patients and it 
is also highly permeable to the biological membranes. P. aeruginosa causes developing 
loss of pulmonary function which leads to premature death in the majority of cystic 
fibrosis patient(Goldberg & Pier, 2000; Lau et al., 2004). It was found that mutations in 
lasR-lasI, rhlR-rhlI and the mvfR-haq QS systems caused loss in pyocyanin 
production(Cao et al., 2001; Gallagher et al., 2002). These QS systems are also involved 
in production of among others, rhamnolipids, proteases and elastase (Lau et al., 2004).  
Pyocyanin formation involved a multifactorial system and though extracts of M. 
lunu-ankenda, P. betle and G. gnemon crude extracts could significantly inhibit its 
production in this study, the mechanism on how the inhibition occurs has yet to be 
established. As for QS inhibitors such as garlic, a downstream study was conducted to 
find out which genes of P. aeruginosa were affected by the extracts. It was found that 
lasA, lasB, rhlAB and chiC genes were downregulated by garlic extract. These genes are 
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essential for the pathogenesis of P. aeruginosa. lasA and lasB are involved in encoding 
elastase and protease, rhlAB encodes rhamnolipids and pyocyanin while chiC encodes 
chitinase (Rasmussen et al., 2005). 
S. aromaticum, Myristica cinnamomea, A. comosus and Musa paradiciacaare 
among the few types of plants found to possess compounds that can inhibit pyocyanin 
production besides M. lunu-ankenda, P. betle and G. gnemon(Chong et al., 2011; 
Krishnan et al.,  2012; Musthafa et al., 2010). Catechin, a type of flavonoid found in 
Combretum albiflorum was found to be able to reduce pyocyanin production in P. 
aeruginosa PA01 (Vandeputte et al., 2010). 
The name P. aeruginosa PA01 lecA::lux means that a luxCDABE gene region 
was cloned to the region of lecA in P. aeruginosa PA01 in such a way every time lecA 
gene is activated or expressed, the lux region will also be activated, thus 
bioluminescence is detected (Winzer et al., 2000). lecA produced by P. aeruginosa is a 
known adhesion and cytotoxic lectin which binds hydrophobic galactosides with high 
specificity and affinity. Study has shown that lecA expression can be found in biofilm-
grown cells and the results suggested that lecA expressed may aid P. aeruginosa biofilm 
structure development under various environmental conditions (Diggle et al., 2006). 
Results obtain from this study found that only three out of the total 12 extracts from M. 
lunu-ankenda, P. betle, P. nigrum and G. gnemon showed significant inhibition against 
lecA expresison. It is, however a very promising results considering the pathogenicity 
that can be caused by lecA. To the best of our knowledge, S. aromaticum is the only 
plant other than G. gnemon and P. betle to cause inhibition against of lecA expression 
(Krishnan et al., 2012). 
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Swarming motility of P. aeruginosa can be divided into three general stages, 
firstly, differentiation of vegetative cells into swarmer cells, followed by migration of 
swarmer cell populations and finally consolidation(Eberl et al., 1999; Kearns, 
2010).Swarming is a bacterial surface translocation process which is QS-dependent and 
requires flagella and pili. Other types of surface translocation characteristic used by the 
bacteria include swimming, gliding, twitching, sliding and darting(Köhler et al., 2000; 
Sharma & Anand, 2002). Swarming usually occurs on semi-solid agar and this motion 
enables the cell to colonize the surrounding surfaces(Sharma & Anand, 2002).  
The optimized swarming agar in this study comprised of 0.5% (w/v) agar. When 
the agar content was lower than 0.5%, P. aeruginosa PA01 swims instead of swarm. 
Subsequently, when the agar was content higher than 0.5%, it was too dry for the 
bacteria and the swarming motion took longer than 20 h to occur. The chloroform 
extract of M. lunu-ankendaand the methanol extract of P. betlemight be exerting its 
inhibition of swarming during the migration of swarmer cells or causing biofilm 
dispersal. As the concentration of the crude extract increases, extend of swarming 
inhibition become more apparent. Similar observation has also been observed in 
malabaricone C, a compound purified from nut meg extract (Chong et al., 2011).  
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Extracts that showed inhibition against swarming has a higher chances of 
inhibiting biofilm regulation as swarming is involved in the biofilm formation through 
mass translocation of cells. In consistence with our finding, Areca catechu, Panax 
ginseng and Prunus armeniaca are among the traditional Chinese medicinal plants that 
were found to contain compounds with anti-swarming activity against P. aeruginosa. 
The extracts from the seeds of A. catechu has the highest area of colony reduction as 
compare with the control (Issac et al., 2011; Koh & Tham, 2011).  
P. aeruginosa is not the only bacteria which exhibits swarming motility. Proteus 
mirabilis, Serratia marcescens and S. liquifaciens also exhibits swarming motility. 
These bacteria have been used by studies in search of QS antagonists. Extracts from 
Capparis spinosaand halogenated furanones from D. pulchrawere reported to be 
inhibiting swarming motility in P. mirabilis and S. marascecens(Givskov et al., 1996; 
Gram et al., 1996; Issac et al., 2011). The halogenated furanones from D. pulchra was 
the first compound discovered from non-bacteria origin to exhibit anti-QS properties. 
The furanones were found to be binding to the LuxR proteins competitively and this in 
turn increased their rate of proteolytic degradation without the need to kill the bacteria 
(Givskov et al., 1996; Manefield et al., 1999; Manefield et al., 2002). 
It is not clear at which level QS has been modulated by these extracts because the 
extracts could be competing or disrupting the AHLs binding to the receptors by 
degradation of AHLs; blocking AHLs from forming AHL-receptor complex; changing 
the structures of the enzymes that is involved AHLs synthesis(Hong et al., 2012). 
Variation in the results between the crude extracts of the same plants showed that each 
crude extracts contains different compounds with varying degree of inhibitions. This is 
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further explored in the following steps of this study, which involves fractionation of the 
crude extracts that showed anti-QS in the assays performed. 
5.3 Bioassay-Guided Fractionation of M. lunu-ankenda Chloroform Extract 
  Fractionation of M. lunu-ankenda chloroform extract was performed using 
Agilent Technologies 1260 Infinity Series HPLC system. This crude extract was 
selected to be fractionated because it inhibited most of the anti-QS assays and to the best 
of our knowledge, fractionation of the chloroform extract of M. lunu-ankenda has yet to 
be reported.  
 In most practice, before performing fractionation on a preparative catridge, the 
sample will be analyzed using an analytical column. We tried to employ this practice but 
the preparative system that we have did not have a degasser and as a consequence, 
bubble was introduced into the analytical column. Thus, instead of performing a scale-
up fractionation from analytical to preparative scale, the latter was choosen for the 
fractionation optimization of M. lunu-ankenda chloroform extract. After approximately 
three weeks, the best method for fractionation of M. lunu-ankenda chloroform extract 
was established and a full run was conducted to begin the collection of the plant 
fractions. Mixtures of acetonitrile and ultrapure water coupled with the usage of C18 
column makes the mode of fractionation used as reversed-phase preparative HPLC. 
 Fractions were collected based on the peaks observed in the chromatogram at 
absorbance of 210 nm starting from the 4
th
 min. The crude extracts fraction peaks were 
best observed at 210 nm. Alkaloids and agylcones are the group of compounds which 
can be extracted by chloroform. Majority of alkaloids are basic and they have medium 
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polarity. Aglycones are the non-sugar moiety of glycosides. Generally, aglycones can be 
obtained from glycosides through hydrolysation of glycosides in aqueous medium 
(Houghton & Raman, 1998).  Thus, the compounds from the chloroform crude extract of 
M. lunu-ankenda may consist of mixtures of both alkaloids and aglycones. To the best of 
our knowledge, phytochemical studies of various parts of M. lunu-ankenda can be found 
from the year 1985 till present (Kumar et al., 1990; Manandhar et al., 1985; Mohan et 
al., 1985; Rastogi & Mehrotra, 1990). Monoterpene hydrocarbons, oxygenated 
monoterpenes, sesquiterpene hydrocarbons, oxygenated sesquiterpenes, eviodione and 
leptonol was found in the leaves oil of M. lunu-ankenda through gas chromatographic 
analysis. Leptonol and evodione have shown anti-inflammatory, anti-pyretic and anti-
oxidant properties (Johnson et al., 2010). Stem wood of M. lunu-ankenda contains a type 
of alkaloid known as evolitrine which has anti-feedant activity (Lal et al., 2005).  
  The crude extract has shown positive inhibition against E. coli [pSB401] and 
swarming motility of P. aeruginosa PA01. After testing the fractions on these two 
assays, we found that the fractions were able to inhibit those QS traits at a lower 
concentration as compared to the crude extract. Fraction 4 and Fraction 11-Fraction 14 
gave significant inhibition against E. coli [pSB401] while for swarming motility, 
Fraction 5 and Fraction 11 gave positive inhibition. The results that we obtain from the 
bioassays performed on those collected fraction proved that the fractionation method in 
this study which employs isocratic elution of mobile phases was successful. Not all of 
the fractions gave significant inhibition, which suggests that the compounds that were 
exerting the inhibition have been categorized accurately into their respective fractions. 
Inactive compounds that were masking the active compounds activity may have been 
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fractionated into a different vial, thus the active fractions was able to inhibit at a lower 
concentration. 
  Though the crude extract did not have any significant inhibition against P. 
aeruginosa PA01 lecA::lux, the fractions were tested for this bioassay as well. Since the 
mixture of crude extract has been fractionated, it is worthwhile to determine whether 
there are any active compounds that could be inhibited by other unwanted compounds in 
the crude extract previously. From the results obtain, we concluded that the chloroform 
extracts of M. lunu-ankenda did not contain active compounds that can cause inhibition 
against P. aeruginosa PA01 lecA::luxas none of the fractions showed significant 
inhibition against this bacteria. If M. lunu-ankenda chloroform extracts contains active 
compounds that could have inhibited the lecA expression, one or some of the fractions 
would have given positive results though the crude did not inhibited the expression. 
Fractions that were eluded later was said to have a higher affinity to the column. Thus, 
fractions that were collected earlier were the most polar while the fractions eluded at a 
later time were the least polar. 
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5.4 Future Work 
 The identity of the compounds from the active fractions has yet to be established. 
Gas chromatography-mass spectrometry (GC-MS) and nuclear magnetic resonance 
(NMR) are among the two machines that can be used to identify the compounds that are 
responsible for those significant inhibitions. In addition, it is also important for us to 
know what mechanisms that were inhibited by those active compounds as it might be 
possible to overcome the problems posed by emerging antibiotic-resistant bacteria. 
Continuous screening of new Malaysia‟s local plant for anti-QS activity is also vital as 
massive amount of flora in Malaysia has yet to be tested for anti-QS. This massive flora 
diversity may one day provide us with an effective new library of anti-QS compounds.  
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CHAPTER 6 
 CONCLUSION 
 The current work represents the finding of anti-QS activity from M. lunu-
ankenda, P. nigrum, G. gnemon and P. betle against P. aeruginosa PA01, P. aeruginosa 
PA01 lecA::lux, C. violacaeum CV026, E. coli [pSB401] and E. coli [pSB1075]. The 
results from the present work showed that anti-QS compounds are not only found among 
bacteria, but can also be found from non-bacteria origins. One important finding from 
this work is that most of the plant extracts seems to be inhibiting the anti-QS activity 
resulted from short chain AHLs. Before establishing the exact mechanism of inhibition 
exerted by these plant samples, it is vital to determine the compound responsible for the 
activity. It is believed that these samples will be able to provide a new class of anti-QS 
compounds and continuous screening of local Malaysia plant for anti-QS activity will be 
able to yield more new plants with anti-QS inhibitions. 
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